JP6254624B2 - プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール - Google Patents
プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール Download PDFInfo
- Publication number
- JP6254624B2 JP6254624B2 JP2016043107A JP2016043107A JP6254624B2 JP 6254624 B2 JP6254624 B2 JP 6254624B2 JP 2016043107 A JP2016043107 A JP 2016043107A JP 2016043107 A JP2016043107 A JP 2016043107A JP 6254624 B2 JP6254624 B2 JP 6254624B2
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- pyrazole
- carboxylic acid
- benzimidazol
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000004079 Prolyl Hydroxylases Human genes 0.000 title description 72
- 108010043005 Prolyl Hydroxylases Proteins 0.000 title description 72
- 239000003112 inhibitor Substances 0.000 title description 28
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 445
- 125000000217 alkyl group Chemical group 0.000 claims description 64
- 238000011282 treatment Methods 0.000 claims description 47
- 150000003839 salts Chemical class 0.000 claims description 41
- 206010021143 Hypoxia Diseases 0.000 claims description 34
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 32
- 230000005764 inhibitory process Effects 0.000 claims description 27
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 24
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 24
- 230000007954 hypoxia Effects 0.000 claims description 22
- 208000007502 anemia Diseases 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 208000028867 ischemia Diseases 0.000 claims description 14
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 13
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 208000027418 Wounds and injury Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 208000008589 Obesity Diseases 0.000 claims description 7
- 206010052428 Wound Diseases 0.000 claims description 7
- 235000020824 obesity Nutrition 0.000 claims description 7
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 238000005481 NMR spectroscopy Methods 0.000 description 272
- 238000001819 mass spectrum Methods 0.000 description 270
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 269
- 239000000203 mixture Substances 0.000 description 196
- -1 heteroaryl amide compounds Chemical class 0.000 description 137
- 235000019439 ethyl acetate Nutrition 0.000 description 134
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 117
- 239000000243 solution Substances 0.000 description 109
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 109
- 239000011541 reaction mixture Substances 0.000 description 104
- 239000000543 intermediate Substances 0.000 description 89
- 230000002829 reductive effect Effects 0.000 description 86
- 239000012044 organic layer Substances 0.000 description 69
- 238000000034 method Methods 0.000 description 65
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 63
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 61
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 239000012267 brine Substances 0.000 description 58
- 238000006243 chemical reaction Methods 0.000 description 58
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 58
- 239000002904 solvent Substances 0.000 description 58
- 239000000460 chlorine Substances 0.000 description 56
- 238000003818 flash chromatography Methods 0.000 description 55
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 46
- 239000002244 precipitate Substances 0.000 description 46
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 42
- 238000003419 tautomerization reaction Methods 0.000 description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 36
- 239000010410 layer Substances 0.000 description 36
- 239000007787 solid Substances 0.000 description 34
- 239000000047 product Substances 0.000 description 32
- 229920006395 saturated elastomer Polymers 0.000 description 32
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 31
- FSGTULQLEVAYRS-UHFFFAOYSA-N 4,5-dichloro-2-nitroaniline Chemical compound NC1=CC(Cl)=C(Cl)C=C1[N+]([O-])=O FSGTULQLEVAYRS-UHFFFAOYSA-N 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 30
- 210000001519 tissue Anatomy 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- 239000002253 acid Substances 0.000 description 26
- 229940002612 prodrug Drugs 0.000 description 26
- 239000000651 prodrug Substances 0.000 description 26
- 125000001424 substituent group Chemical group 0.000 description 26
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 25
- 239000002585 base Substances 0.000 description 25
- 230000001965 increasing effect Effects 0.000 description 25
- AAMCWLIPRMIPBN-UHFFFAOYSA-N 5-chloro-2-nitro-4-(trifluoromethyl)aniline Chemical compound NC1=CC(Cl)=C(C(F)(F)F)C=C1[N+]([O-])=O AAMCWLIPRMIPBN-UHFFFAOYSA-N 0.000 description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 24
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 24
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 24
- 229910052760 oxygen Inorganic materials 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 22
- 238000000746 purification Methods 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 201000010099 disease Diseases 0.000 description 21
- 238000001914 filtration Methods 0.000 description 21
- AYPSHJCKSDNETA-UHFFFAOYSA-N 2-chloro-1h-benzimidazole Chemical compound C1=CC=C2NC(Cl)=NC2=C1 AYPSHJCKSDNETA-UHFFFAOYSA-N 0.000 description 20
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 19
- 230000033115 angiogenesis Effects 0.000 description 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 19
- 239000001301 oxygen Substances 0.000 description 19
- 238000010992 reflux Methods 0.000 description 19
- 210000000130 stem cell Anatomy 0.000 description 19
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- KACZQOKEFKFNDB-UHFFFAOYSA-N ethyl 1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1 KACZQOKEFKFNDB-UHFFFAOYSA-N 0.000 description 18
- 229960000583 acetic acid Drugs 0.000 description 17
- 125000001309 chloro group Chemical group Cl* 0.000 description 17
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
- NFVAJIPVDHPZKP-UHFFFAOYSA-N 5-chloro-2-nitro-4-(trifluoromethoxy)aniline Chemical compound NC1=CC(Cl)=C(OC(F)(F)F)C=C1[N+]([O-])=O NFVAJIPVDHPZKP-UHFFFAOYSA-N 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 16
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 15
- 230000000302 ischemic effect Effects 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- YADOEPHJIBKBCN-UHFFFAOYSA-N 3-chloro-2-nitroaniline Chemical compound NC1=CC=CC(Cl)=C1[N+]([O-])=O YADOEPHJIBKBCN-UHFFFAOYSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 102000003951 Erythropoietin Human genes 0.000 description 14
- 108090000394 Erythropoietin Proteins 0.000 description 14
- 229940105423 erythropoietin Drugs 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 14
- SUVIGLJNEAMWEG-UHFFFAOYSA-N propane-1-thiol Chemical compound CCCS SUVIGLJNEAMWEG-UHFFFAOYSA-N 0.000 description 14
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 12
- 101100441092 Danio rerio crlf3 gene Proteins 0.000 description 12
- 101710111663 Egl nine homolog 1 Proteins 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- KJRCEJOSASVSRA-UHFFFAOYSA-N propane-2-thiol Chemical compound CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 12
- BIAAQBNMRITRDV-UHFFFAOYSA-N 1-(chloromethoxy)-2-methoxyethane Chemical compound COCCOCCl BIAAQBNMRITRDV-UHFFFAOYSA-N 0.000 description 11
- WDNBURPWRNALGP-UHFFFAOYSA-N 3,4-Dichlorophenol Chemical compound OC1=CC=C(Cl)C(Cl)=C1 WDNBURPWRNALGP-UHFFFAOYSA-N 0.000 description 11
- 102100037249 Egl nine homolog 1 Human genes 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 125000004494 ethyl ester group Chemical group 0.000 description 10
- 230000001146 hypoxic effect Effects 0.000 description 10
- WRXOZRLZDJAYDR-UHFFFAOYSA-N 3-methylbenzenethiol Chemical compound CC1=CC=CC(S)=C1 WRXOZRLZDJAYDR-UHFFFAOYSA-N 0.000 description 9
- WDMCABATCGQAKK-UHFFFAOYSA-N 4,5-difluoro-2-nitroaniline Chemical compound NC1=CC(F)=C(F)C=C1[N+]([O-])=O WDMCABATCGQAKK-UHFFFAOYSA-N 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 9
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- ZSNYOIJMFZLJES-UHFFFAOYSA-N [3-[(3-chlorophenyl)methoxy]phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(OCC=2C=C(Cl)C=CC=2)=C1 ZSNYOIJMFZLJES-UHFFFAOYSA-N 0.000 description 9
- 150000001408 amides Chemical class 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000002207 metabolite Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 9
- 230000029663 wound healing Effects 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- SAIXZIVDXDTYCH-UHFFFAOYSA-N 3-chlorobenzene-1,2-diamine Chemical compound NC1=CC=CC(Cl)=C1N SAIXZIVDXDTYCH-UHFFFAOYSA-N 0.000 description 7
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- LAFJKNNJXYUZTN-UHFFFAOYSA-N ethyl 1-[5-amino-6-chloro-1-(2-methoxyethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(N)=C(Cl)C=C2N1COCCOC LAFJKNNJXYUZTN-UHFFFAOYSA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 7
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 239000006227 byproduct Substances 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- 239000013058 crude material Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002808 molecular sieve Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 6
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- SPSSDDOTEZKOOV-UHFFFAOYSA-N 2,3-dichloroquinoxaline Chemical compound C1=CC=C2N=C(Cl)C(Cl)=NC2=C1 SPSSDDOTEZKOOV-UHFFFAOYSA-N 0.000 description 5
- SUQYOUJCBGMSLV-UHFFFAOYSA-N 2,5,6-trichloro-1h-benzimidazole Chemical compound ClC1=C(Cl)C=C2NC(Cl)=NC2=C1 SUQYOUJCBGMSLV-UHFFFAOYSA-N 0.000 description 5
- YQTYHIPXZXVCHV-UHFFFAOYSA-N 4-chloro-5-(3-methylphenyl)sulfanyl-2-nitroaniline Chemical compound CC1=CC=CC(SC=2C(=CC(=C(N)C=2)[N+]([O-])=O)Cl)=C1 YQTYHIPXZXVCHV-UHFFFAOYSA-N 0.000 description 5
- OIPJNAYUGRIEKT-UHFFFAOYSA-N 4-chloro-5-(3-methylphenyl)sulfanylbenzene-1,2-diamine Chemical compound CC1=CC=CC(SC=2C(=CC(N)=C(N)C=2)Cl)=C1 OIPJNAYUGRIEKT-UHFFFAOYSA-N 0.000 description 5
- 239000005973 Carvone Substances 0.000 description 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 230000003511 endothelial effect Effects 0.000 description 5
- MCKKOKYTZHQXCD-UHFFFAOYSA-N ethyl 1-[1-(2-methoxyethoxymethyl)-6-methylsulfanyl-5-(trifluoromethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(C(F)(F)F)=C(SC)C=C2N1COCCOC MCKKOKYTZHQXCD-UHFFFAOYSA-N 0.000 description 5
- HFQZFGYRROHRCV-UHFFFAOYSA-N ethyl 1-[6-chloro-1-(2-methoxyethoxymethyl)-5-(3-methylphenyl)sulfanylbenzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(SC=3C=C(C)C=CC=3)=C(Cl)C=C2N1COCCOC HFQZFGYRROHRCV-UHFFFAOYSA-N 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 230000034659 glycolysis Effects 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 4
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 239000012425 OXONE® Substances 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 4
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 102100035194 Placenta growth factor Human genes 0.000 description 4
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- PFWWSGFPICCWGU-UHFFFAOYSA-N cyclopropanesulfonyl chloride Chemical compound ClS(=O)(=O)C1CC1 PFWWSGFPICCWGU-UHFFFAOYSA-N 0.000 description 4
- 150000004985 diamines Chemical class 0.000 description 4
- YHXDTNVEMCGBSV-UHFFFAOYSA-N ethyl 1-(5-benzylsulfanyl-6-chloro-1h-benzimidazol-2-yl)pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(SCC=3C=CC=CC=3)=C(Cl)C=C2N1 YHXDTNVEMCGBSV-UHFFFAOYSA-N 0.000 description 4
- RXOWBUQOIRRSRR-UHFFFAOYSA-N ethyl 1-[5-benzylsulfanyl-6-chloro-1-(2-methoxyethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(SCC=3C=CC=CC=3)=C(Cl)C=C2N1COCCOC RXOWBUQOIRRSRR-UHFFFAOYSA-N 0.000 description 4
- 102000018511 hepcidin Human genes 0.000 description 4
- 108060003558 hepcidin Proteins 0.000 description 4
- 229940066919 hepcidin Drugs 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 229940076788 pyruvate Drugs 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- NQHKCHWQDDWQJR-UHFFFAOYSA-M sodium;propane-2-thiolate Chemical compound [Na+].CC(C)[S-] NQHKCHWQDDWQJR-UHFFFAOYSA-M 0.000 description 4
- 239000008279 sol Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000000707 stereoselective effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- FQKGMOOXMBVYKA-UHFFFAOYSA-N 1-(5,6-dichloro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(Cl)=C(Cl)C=C2N1 FQKGMOOXMBVYKA-UHFFFAOYSA-N 0.000 description 3
- GSRJTKUZYYJTHC-UHFFFAOYSA-N 1-(5-benzylsulfanyl-6-chloro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SCC=3C=CC=CC=3)=C(Cl)C=C2N1 GSRJTKUZYYJTHC-UHFFFAOYSA-N 0.000 description 3
- LCONLFPNVNSXLQ-UHFFFAOYSA-N 1-[5-chloro-6-(phenylsulfamoyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)NC=3C=CC=CC=3)=C(Cl)C=C2N1 LCONLFPNVNSXLQ-UHFFFAOYSA-N 0.000 description 3
- CEONFCKACMSKDJ-UHFFFAOYSA-N 1-[6-chloro-5-(ethylamino)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(Cl)C(NCC)=CC=2N=C1N1C=C(C(O)=O)C=N1 CEONFCKACMSKDJ-UHFFFAOYSA-N 0.000 description 3
- FXHHASJVTYRJHH-UHFFFAOYSA-N 1-[6-chloro-5-(trifluoromethoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(Cl)=C(OC(F)(F)F)C=C2N1 FXHHASJVTYRJHH-UHFFFAOYSA-N 0.000 description 3
- OWIRVNDMYDSKIJ-UHFFFAOYSA-N 2,4-dichloro-1h-benzimidazole Chemical compound C1=CC=C2NC(Cl)=NC2=C1Cl OWIRVNDMYDSKIJ-UHFFFAOYSA-N 0.000 description 3
- VHPLZFGCNLDYQH-UHFFFAOYSA-N 2,6-dibromo-4-fluoroaniline Chemical compound NC1=C(Br)C=C(F)C=C1Br VHPLZFGCNLDYQH-UHFFFAOYSA-N 0.000 description 3
- ATXBGHLILIABGX-UHFFFAOYSA-N 2-nitro-4-(trifluoromethyl)aniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1[N+]([O-])=O ATXBGHLILIABGX-UHFFFAOYSA-N 0.000 description 3
- DPJCXCZTLWNFOH-UHFFFAOYSA-N 2-nitroaniline Chemical compound NC1=CC=CC=C1[N+]([O-])=O DPJCXCZTLWNFOH-UHFFFAOYSA-N 0.000 description 3
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- LNMLENQCZLQTDO-UHFFFAOYSA-N 4-chloro-2-nitro-5-pyrrolidin-1-ylaniline Chemical compound C1=C([N+]([O-])=O)C(N)=CC(N2CCCC2)=C1Cl LNMLENQCZLQTDO-UHFFFAOYSA-N 0.000 description 3
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 3
- FVPIRIXHKGWBJP-UHFFFAOYSA-N 5-chloro-2-nitro-4-phenoxyaniline Chemical compound C1=C([N+]([O-])=O)C(N)=CC(Cl)=C1OC1=CC=CC=C1 FVPIRIXHKGWBJP-UHFFFAOYSA-N 0.000 description 3
- QVVZVWKGWGFUTA-UHFFFAOYSA-N 6-bromo-2-chloro-1h-benzimidazole Chemical compound BrC1=CC=C2NC(Cl)=NC2=C1 QVVZVWKGWGFUTA-UHFFFAOYSA-N 0.000 description 3
- CXSYIYZNBBITDC-UHFFFAOYSA-N 6-chloro-5-(3-methylphenyl)sulfanyl-1h-benzimidazole Chemical compound CC1=CC=CC(SC=2C(=CC=3NC=NC=3C=2)Cl)=C1 CXSYIYZNBBITDC-UHFFFAOYSA-N 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 102000009088 Angiopoietin-1 Human genes 0.000 description 3
- 108010048154 Angiopoietin-1 Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229910014265 BrCl Inorganic materials 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 3
- 108010082093 Placenta Growth Factor Proteins 0.000 description 3
- 101710170760 Prolyl hydroxylase EGLN2 Proteins 0.000 description 3
- 102100037248 Prolyl hydroxylase EGLN2 Human genes 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 101001117144 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) [Pyruvate dehydrogenase (acetyl-transferring)] kinase 1, mitochondrial Proteins 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000006538 anaerobic glycolysis Effects 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000012455 biphasic mixture Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- CODNYICXDISAEA-UHFFFAOYSA-N bromine monochloride Chemical compound BrCl CODNYICXDISAEA-UHFFFAOYSA-N 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- XJHCXCQVJFPJIK-UHFFFAOYSA-M cesium fluoride Substances [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229960000958 deferoxamine Drugs 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- BIAZSCQHIYLXAK-UHFFFAOYSA-N ethyl 1-[6-ethylsulfanyl-1-(2-methoxyethoxymethyl)-5-(trifluoromethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(C(F)(F)F)=C(SCC)C=C2N1COCCOC BIAZSCQHIYLXAK-UHFFFAOYSA-N 0.000 description 3
- VKWPQZBRDYWMKQ-UHFFFAOYSA-N ethyl 5-carbamimidoyl-1H-pyrazole-4-carboxylate Chemical compound CCOC(=O)C1=CNN=C1C(N)=N VKWPQZBRDYWMKQ-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 3
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000002530 ischemic preconditioning effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- FPLNOWDFOVYQEK-UHFFFAOYSA-N methyl 2-chloro-1-(2-methoxyethoxymethyl)benzimidazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2N(COCCOC)C(Cl)=NC2=C1 FPLNOWDFOVYQEK-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 238000006396 nitration reaction Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000007959 normoxia Effects 0.000 description 3
- 238000005580 one pot reaction Methods 0.000 description 3
- 230000002669 organ and tissue protective effect Effects 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000010627 oxidative phosphorylation Effects 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 125000004001 thioalkyl group Chemical group 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- NMWPADNRTKOZPD-UHFFFAOYSA-N (2,6-dibromo-4-fluorophenyl)cyanamide Chemical compound FC1=CC(Br)=C(NC#N)C(Br)=C1 NMWPADNRTKOZPD-UHFFFAOYSA-N 0.000 description 2
- LIWUZLARXGNOOW-UHFFFAOYSA-N (2,6-dibromo-4-fluorophenyl)thiourea Chemical compound NC(=S)NC1=C(Br)C=C(F)C=C1Br LIWUZLARXGNOOW-UHFFFAOYSA-N 0.000 description 2
- NTNKNFHIAFDCSJ-UHFFFAOYSA-N (2-nitrophenyl) thiohypochlorite Chemical compound [O-][N+](=O)C1=CC=CC=C1SCl NTNKNFHIAFDCSJ-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- PHNMBIXTDLCXJO-UHFFFAOYSA-N 1-(1h-benzimidazol-2-yl)-5-methylpyrazole-4-carboxylic acid Chemical compound CC1=C(C(O)=O)C=NN1C1=NC2=CC=CC=C2N1 PHNMBIXTDLCXJO-UHFFFAOYSA-N 0.000 description 2
- NKHFZTBINPZYFH-UHFFFAOYSA-N 1-(1h-imidazo[4,5-b]quinoxalin-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=NC3=CC=CC=C3N=C2N1 NKHFZTBINPZYFH-UHFFFAOYSA-N 0.000 description 2
- MGVJGAFQTTYTEG-UHFFFAOYSA-N 1-(4,5,6-trichloro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=C(Cl)C(Cl)=C(Cl)C=C2N1 MGVJGAFQTTYTEG-UHFFFAOYSA-N 0.000 description 2
- PDURPECWBLHITL-UHFFFAOYSA-N 1-(4-bromo-5,6-dichloro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=C(Br)C(Cl)=C(Cl)C=C2N1 PDURPECWBLHITL-UHFFFAOYSA-N 0.000 description 2
- SMOLRMXZIMDKTJ-UHFFFAOYSA-N 1-(4-bromo-6-fluoro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=C(Br)C=C(F)C=C2N1 SMOLRMXZIMDKTJ-UHFFFAOYSA-N 0.000 description 2
- NIEDUYNXNPIRAA-UHFFFAOYSA-N 1-(4-chloro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=C(Cl)C=CC=C2N1 NIEDUYNXNPIRAA-UHFFFAOYSA-N 0.000 description 2
- VCZYPTVNCSPIRP-UHFFFAOYSA-N 1-(5-acetamido-6-chloro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(Cl)C(NC(=O)C)=CC=2N=C1N1C=C(C(O)=O)C=N1 VCZYPTVNCSPIRP-UHFFFAOYSA-N 0.000 description 2
- ANNCAEPHNBPDEZ-UHFFFAOYSA-N 1-(5-amino-6-chloro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(Cl)C(N)=CC=2N=C1N1C=C(C(O)=O)C=N1 ANNCAEPHNBPDEZ-UHFFFAOYSA-N 0.000 description 2
- XHVFRFRKXSWFEZ-UHFFFAOYSA-N 1-(5-anilino-6-chloro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(NC=3C=CC=CC=3)=C(Cl)C=C2N1 XHVFRFRKXSWFEZ-UHFFFAOYSA-N 0.000 description 2
- VGNYEUNNLSOMGH-UHFFFAOYSA-N 1-(5-bromo-6-fluoro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(F)=C(Br)C=C2N1 VGNYEUNNLSOMGH-UHFFFAOYSA-N 0.000 description 2
- TWVFMVNVAUKJNZ-UHFFFAOYSA-N 1-(5-chloro-6-ethylsulfinyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(Cl)C(S(=O)CC)=CC=2NC=1N1C=C(C(O)=O)C=N1 TWVFMVNVAUKJNZ-UHFFFAOYSA-N 0.000 description 2
- JQSUSMZMRBCOON-UHFFFAOYSA-N 1-(5-chloro-6-ethylsulfonyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(Cl)C(S(=O)(=O)CC)=CC=2NC=1N1C=C(C(O)=O)C=N1 JQSUSMZMRBCOON-UHFFFAOYSA-N 0.000 description 2
- OLBQXWOEVGSIIM-UHFFFAOYSA-N 1-(5-chloro-6-propan-2-ylsulfonyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(Cl)C(S(=O)(=O)C(C)C)=CC=2NC=1N1C=C(C(O)=O)C=N1 OLBQXWOEVGSIIM-UHFFFAOYSA-N 0.000 description 2
- NHPISMRFUZMNCV-UHFFFAOYSA-N 1-(5-chloro-6-propylsulfonyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(Cl)C(S(=O)(=O)CCC)=CC=2NC=1N1C=C(C(O)=O)C=N1 NHPISMRFUZMNCV-UHFFFAOYSA-N 0.000 description 2
- IOZGVJSQFKYJKA-UHFFFAOYSA-N 1-(5-fluoro-4-methyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C=2C(C)=C(F)C=CC=2NC=1N1C=C(C(O)=O)C=N1 IOZGVJSQFKYJKA-UHFFFAOYSA-N 0.000 description 2
- BFXZSKJHCZFHMH-UHFFFAOYSA-N 1-(6-bromo-4-fluoro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(Br)=CC(F)=C2N1 BFXZSKJHCZFHMH-UHFFFAOYSA-N 0.000 description 2
- FEXAJBGZDJLQBO-UHFFFAOYSA-N 1-(6-chloro-5-methoxy-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(Cl)C(OC)=CC=2N=C1N1C=C(C(O)=O)C=N1 FEXAJBGZDJLQBO-UHFFFAOYSA-N 0.000 description 2
- IAPVIQKGWOOCJG-UHFFFAOYSA-N 1-(6-chloro-5-morpholin-4-yl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(N3CCOCC3)=C(Cl)C=C2N1 IAPVIQKGWOOCJG-UHFFFAOYSA-N 0.000 description 2
- FAJDDQGAGIXRRT-UHFFFAOYSA-N 1-(6-chloro-5-phenoxy-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(OC=3C=CC=CC=3)=C(Cl)C=C2N1 FAJDDQGAGIXRRT-UHFFFAOYSA-N 0.000 description 2
- WDOBTSBBJYXXNS-UHFFFAOYSA-N 1-(6-chloro-5-phenylmethoxy-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(OCC=3C=CC=CC=3)=C(Cl)C=C2N1 WDOBTSBBJYXXNS-UHFFFAOYSA-N 0.000 description 2
- APUAYJKPBSERSO-UHFFFAOYSA-N 1-(6-chloro-5-piperidin-1-yl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(N3CCCCC3)=C(Cl)C=C2N1 APUAYJKPBSERSO-UHFFFAOYSA-N 0.000 description 2
- XNWSEVGIKOKJBZ-UHFFFAOYSA-N 1-(6-fluoro-5-propylsulfanyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(F)C(SCCC)=CC=2N=C1N1C=C(C(O)=O)C=N1 XNWSEVGIKOKJBZ-UHFFFAOYSA-N 0.000 description 2
- GKPHFNFGAZPISY-UHFFFAOYSA-N 1-[5-(3,4-dichlorophenoxy)-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(OC=3C=C(Cl)C(Cl)=CC=3)=C(C(F)(F)F)C=C2N1 GKPHFNFGAZPISY-UHFFFAOYSA-N 0.000 description 2
- MBYIBVBJTOONKJ-UHFFFAOYSA-N 1-[5-(benzylamino)-6-chloro-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(NCC=3C=CC=CC=3)=C(Cl)C=C2N1 MBYIBVBJTOONKJ-UHFFFAOYSA-N 0.000 description 2
- YHIPPOAJRPXQIE-UHFFFAOYSA-N 1-[5-chloro-6-(3-methylphenyl)sulfonyl-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound CC1=CC=CC(S(=O)(=O)C=2C(=CC=3NC(=NC=3C=2)N2N=CC(=C2)C(O)=O)Cl)=C1 YHIPPOAJRPXQIE-UHFFFAOYSA-N 0.000 description 2
- KQWOOZWULBSGMX-UHFFFAOYSA-N 1-[5-chloro-6-(4-chlorophenyl)sulfonyl-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)C=3C=CC(Cl)=CC=3)=C(Cl)C=C2N1 KQWOOZWULBSGMX-UHFFFAOYSA-N 0.000 description 2
- YVXDWFRUNSSAIK-UHFFFAOYSA-N 1-[5-chloro-6-[(2,4,6-trimethylphenyl)methylsulfonyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound CC1=CC(C)=CC(C)=C1CS(=O)(=O)C(C(=C1)Cl)=CC2=C1NC(N1N=CC(=C1)C(O)=O)=N2 YVXDWFRUNSSAIK-UHFFFAOYSA-N 0.000 description 2
- OHRLKYYIBYULOB-UHFFFAOYSA-N 1-[5-chloro-6-[(4-methoxyphenyl)methylsulfonyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1CS(=O)(=O)C(C(=C1)Cl)=CC2=C1NC(N1N=CC(=C1)C(O)=O)=N2 OHRLKYYIBYULOB-UHFFFAOYSA-N 0.000 description 2
- JMVOEXZKWJTVQP-UHFFFAOYSA-N 1-[5-chloro-6-[4-(trifluoromethoxy)phenyl]sulfonyl-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)C=3C=CC(OC(F)(F)F)=CC=3)=C(Cl)C=C2N1 JMVOEXZKWJTVQP-UHFFFAOYSA-N 0.000 description 2
- ICCAPIMPXFYEEI-UHFFFAOYSA-N 1-[5-ethylsulfanyl-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(C(F)(F)F)C(SCC)=CC=2N=C1N1C=C(C(O)=O)C=N1 ICCAPIMPXFYEEI-UHFFFAOYSA-N 0.000 description 2
- BVKQYJRNNQGISO-UHFFFAOYSA-N 1-[5-methylsulfanyl-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(C(F)(F)F)C(SC)=CC=2NC=1N1C=C(C(O)=O)C=N1 BVKQYJRNNQGISO-UHFFFAOYSA-N 0.000 description 2
- OSKPMKMIUNDZBD-UHFFFAOYSA-N 1-[5-methylsulfinyl-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(C(F)(F)F)C(S(=O)C)=CC=2NC=1N1C=C(C(O)=O)C=N1 OSKPMKMIUNDZBD-UHFFFAOYSA-N 0.000 description 2
- GGWYXZPYXMFLCC-UHFFFAOYSA-N 1-[5-propylsulfanyl-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(C(F)(F)F)C(SCCC)=CC=2NC=1N1C=C(C(O)=O)C=N1 GGWYXZPYXMFLCC-UHFFFAOYSA-N 0.000 description 2
- GZICKMLJCRIRKE-UHFFFAOYSA-N 1-[6-(phenylcarbamoyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C(=O)NC=3C=CC=CC=3)=CC=C2N1 GZICKMLJCRIRKE-UHFFFAOYSA-N 0.000 description 2
- KFJOODNNFWKCOD-UHFFFAOYSA-N 1-[6-(phenylmethoxymethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(COCC=3C=CC=CC=3)=CC=C2N1 KFJOODNNFWKCOD-UHFFFAOYSA-N 0.000 description 2
- SAHAFELAYUNCQY-UHFFFAOYSA-N 1-[6-[3-[(3-chlorophenyl)methoxy]phenyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C=3C=C(OCC=4C=C(Cl)C=CC=4)C=CC=3)=CC=C2N1 SAHAFELAYUNCQY-UHFFFAOYSA-N 0.000 description 2
- QQFPRSHPPVLPOY-UHFFFAOYSA-N 1-[6-chloro-5-(2-morpholin-4-ylethylamino)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(NCCN3CCOCC3)=C(Cl)C=C2N1 QQFPRSHPPVLPOY-UHFFFAOYSA-N 0.000 description 2
- USHZYJYMWPJFJL-UHFFFAOYSA-N 1-[6-chloro-5-(3-methylphenyl)sulfanyl-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound CC1=CC=CC(SC=2C(=CC=3NC(=NC=3C=2)N2N=CC(=C2)C(O)=O)Cl)=C1 USHZYJYMWPJFJL-UHFFFAOYSA-N 0.000 description 2
- QQHXMRHWHIKZFC-UHFFFAOYSA-N 1-[6-chloro-5-(cyclopropylsulfonylamino)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(NS(=O)(=O)C3CC3)=C(Cl)C=C2N1 QQHXMRHWHIKZFC-UHFFFAOYSA-N 0.000 description 2
- SOFBMFATKMVEEC-UHFFFAOYSA-N 1-[6-chloro-5-[(2-morpholin-4-ylacetyl)amino]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(NC(=O)CN3CCOCC3)=C(Cl)C=C2N1 SOFBMFATKMVEEC-UHFFFAOYSA-N 0.000 description 2
- IGKOJGNVPPHLEH-UHFFFAOYSA-N 1-[6-piperidin-1-yl-5-(trifluoromethoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(N3CCCCC3)=C(OC(F)(F)F)C=C2N1 IGKOJGNVPPHLEH-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CCFLXWNBCHDBHK-UHFFFAOYSA-N 2,3,4-trichloro-6-nitroaniline Chemical compound NC1=C(Cl)C(Cl)=C(Cl)C=C1[N+]([O-])=O CCFLXWNBCHDBHK-UHFFFAOYSA-N 0.000 description 2
- SMHBVUDUNDQEJA-UHFFFAOYSA-N 2,4,5,6-tetrachloro-1-(2-methoxyethoxymethyl)benzimidazole Chemical compound ClC1=C(Cl)C=C2N(COCCOC)C(Cl)=NC2=C1Cl SMHBVUDUNDQEJA-UHFFFAOYSA-N 0.000 description 2
- YFHMKXNVRGEUCE-UHFFFAOYSA-N 2,4-dichloro-1-(2-methoxyethoxymethyl)benzimidazole Chemical compound C1=CC=C2N(COCCOC)C(Cl)=NC2=C1Cl YFHMKXNVRGEUCE-UHFFFAOYSA-N 0.000 description 2
- FDPJKCAZUUGZGX-UHFFFAOYSA-N 2,5,6-trichloro-n,n-dimethylbenzimidazole-1-sulfonamide Chemical compound ClC1=C(Cl)C=C2N(S(=O)(=O)N(C)C)C(Cl)=NC2=C1 FDPJKCAZUUGZGX-UHFFFAOYSA-N 0.000 description 2
- QXJBUKWMTVFRKY-UHFFFAOYSA-N 2,6-dichloro-1-(2-methoxyethoxymethyl)-5-(3-methylphenyl)sulfanylbenzimidazole Chemical compound ClC=1C=C2N(COCCOC)C(Cl)=NC2=CC=1SC1=CC=CC(C)=C1 QXJBUKWMTVFRKY-UHFFFAOYSA-N 0.000 description 2
- UFXCYRFRRQPFLV-UHFFFAOYSA-N 2,6-dichloro-1-(2-methoxyethoxymethyl)-5-phenoxybenzimidazole Chemical compound ClC=1C=C2N(COCCOC)C(Cl)=NC2=CC=1OC1=CC=CC=C1 UFXCYRFRRQPFLV-UHFFFAOYSA-N 0.000 description 2
- PHUVHVYHYPJIAQ-UHFFFAOYSA-N 2,6-dichloro-5-(trifluoromethoxy)-1h-benzimidazole Chemical compound C1=C(Cl)C(OC(F)(F)F)=CC2=C1NC(Cl)=N2 PHUVHVYHYPJIAQ-UHFFFAOYSA-N 0.000 description 2
- QSETWRXZBYGTKG-UHFFFAOYSA-N 2,6-dichloro-5-nitro-1h-benzimidazole Chemical compound C1=C(Cl)C([N+](=O)[O-])=CC2=C1N=C(Cl)N2 QSETWRXZBYGTKG-UHFFFAOYSA-N 0.000 description 2
- OGVXXOOLPXBODN-UHFFFAOYSA-N 2,6-dichloro-n,n-dimethyl-5-(trifluoromethoxy)benzimidazole-1-sulfonamide Chemical compound FC(F)(F)OC1=C(Cl)C=C2N(S(=O)(=O)N(C)C)C(Cl)=NC2=C1 OGVXXOOLPXBODN-UHFFFAOYSA-N 0.000 description 2
- AXFPCYAFZVFLLG-UHFFFAOYSA-N 2-(4-carboxypyrazol-1-yl)-3h-benzimidazole-5-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C(O)=O)=CC=C2N1 AXFPCYAFZVFLLG-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- MTBFHRDRUBNDLV-UHFFFAOYSA-N 2-[(2-chlorobenzimidazol-1-yl)methoxy]ethyl-trimethylsilane Chemical compound C1=CC=C2N(COCC[Si](C)(C)C)C(Cl)=NC2=C1 MTBFHRDRUBNDLV-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 2
- YGOINKJYRGFUQO-UHFFFAOYSA-N 2-chloro-1-(2-methoxyethoxymethyl)benzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N(COCCOC)C(Cl)=NC2=C1 YGOINKJYRGFUQO-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- YEHAEOUAUDRTJX-UHFFFAOYSA-N 2-nitro-5-piperidin-1-yl-4-(trifluoromethoxy)aniline Chemical compound C1=C([N+]([O-])=O)C(N)=CC(N2CCCCC2)=C1OC(F)(F)F YEHAEOUAUDRTJX-UHFFFAOYSA-N 0.000 description 2
- HNUZFOUBGXNDMR-UHFFFAOYSA-N 4,5,6-trichloro-1-(2-methoxyethoxymethyl)benzimidazole Chemical compound ClC1=C(Cl)C=C2N(COCCOC)C=NC2=C1Cl HNUZFOUBGXNDMR-UHFFFAOYSA-N 0.000 description 2
- QULAOTHQGHPERK-UHFFFAOYSA-N 4,5,6-trichloro-1h-benzimidazole Chemical compound ClC1=C(Cl)C(Cl)=CC2=C1N=CN2 QULAOTHQGHPERK-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VTCHZFWYUPZZKL-UHFFFAOYSA-N 4-azaniumylcyclopent-2-ene-1-carboxylate Chemical compound NC1CC(C(O)=O)C=C1 VTCHZFWYUPZZKL-UHFFFAOYSA-N 0.000 description 2
- JNQKUPMTQQPPJP-UHFFFAOYSA-N 4-chloro-2-nitro-5-propan-2-ylsulfanylaniline Chemical compound CC(C)SC1=CC(N)=C([N+]([O-])=O)C=C1Cl JNQKUPMTQQPPJP-UHFFFAOYSA-N 0.000 description 2
- GKVJYBKEHWXTEF-UHFFFAOYSA-N 4-chloro-5-methoxy-2-nitroaniline Chemical compound COC1=CC(N)=C([N+]([O-])=O)C=C1Cl GKVJYBKEHWXTEF-UHFFFAOYSA-N 0.000 description 2
- NIFAOMSJMGEFTQ-UHFFFAOYSA-N 4-methoxybenzenethiol Chemical compound COC1=CC=C(S)C=C1 NIFAOMSJMGEFTQ-UHFFFAOYSA-N 0.000 description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- HQBYAESCKCDTDJ-UHFFFAOYSA-N 5,6-dichloro-1,3-dihydrobenzimidazol-2-one Chemical compound ClC1=C(Cl)C=C2NC(O)=NC2=C1 HQBYAESCKCDTDJ-UHFFFAOYSA-N 0.000 description 2
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 2
- SVKFZSLMFIKJEA-UHFFFAOYSA-N 5-benzylsulfanyl-4-chloro-2-nitroaniline Chemical compound C1=C([N+]([O-])=O)C(N)=CC(SCC=2C=CC=CC=2)=C1Cl SVKFZSLMFIKJEA-UHFFFAOYSA-N 0.000 description 2
- OZKZRRLKJAXHQA-UHFFFAOYSA-N 5-bromo-3-fluorobenzene-1,2-diamine Chemical compound NC1=CC(Br)=CC(F)=C1N OZKZRRLKJAXHQA-UHFFFAOYSA-N 0.000 description 2
- CRBGRCCXVAWOCO-UHFFFAOYSA-N 5-bromo-4-fluoro-2-nitroaniline Chemical compound NC1=CC(Br)=C(F)C=C1[N+]([O-])=O CRBGRCCXVAWOCO-UHFFFAOYSA-N 0.000 description 2
- DQBISIMZMBPXBW-UHFFFAOYSA-N 5-chloro-6-(trifluoromethoxy)-1,3-dihydrobenzimidazol-2-one Chemical compound C1=C(Cl)C(OC(F)(F)F)=CC2=C1NC(=O)N2 DQBISIMZMBPXBW-UHFFFAOYSA-N 0.000 description 2
- LMGOHSUBTHHMHD-UHFFFAOYSA-N 5-chloro-6-nitro-1,3-dihydrobenzimidazol-2-one Chemical compound C1=C(Cl)C([N+](=O)[O-])=CC2=C1NC(=O)N2 LMGOHSUBTHHMHD-UHFFFAOYSA-N 0.000 description 2
- MCFYBPYPTDSKLJ-UHFFFAOYSA-N 5-methylsulfanyl-2-nitro-4-(trifluoromethyl)aniline Chemical compound CSC1=CC(N)=C([N+]([O-])=O)C=C1C(F)(F)F MCFYBPYPTDSKLJ-UHFFFAOYSA-N 0.000 description 2
- ODWIMNABOZHWIA-UHFFFAOYSA-N 6-chloro-1-(2-methoxyethoxymethyl)-5-(3-methylphenyl)sulfanylbenzimidazole Chemical compound ClC=1C=C2N(COCCOC)C=NC2=CC=1SC1=CC=CC(C)=C1 ODWIMNABOZHWIA-UHFFFAOYSA-N 0.000 description 2
- LELFGYKTLVKONI-UHFFFAOYSA-N 6-chloro-1-(2-methoxyethoxymethyl)-5-phenoxybenzimidazole Chemical compound ClC=1C=C2N(COCCOC)C=NC2=CC=1OC1=CC=CC=C1 LELFGYKTLVKONI-UHFFFAOYSA-N 0.000 description 2
- RAPIBSLFOCQMBW-UHFFFAOYSA-N 6-chloro-5-methoxy-1h-benzimidazole Chemical compound C1=C(Cl)C(OC)=CC2=C1N=CN2 RAPIBSLFOCQMBW-UHFFFAOYSA-N 0.000 description 2
- NPQYIEIUCUWECW-UHFFFAOYSA-N 6-chloro-5-phenoxy-1h-benzimidazole Chemical compound ClC1=CC=2NC=NC=2C=C1OC1=CC=CC=C1 NPQYIEIUCUWECW-UHFFFAOYSA-N 0.000 description 2
- RXEXQAOITSHJBF-UHFFFAOYSA-N 6-chloro-5-pyrrolidin-1-yl-1h-benzimidazole Chemical compound ClC1=CC=2NC=NC=2C=C1N1CCCC1 RXEXQAOITSHJBF-UHFFFAOYSA-N 0.000 description 2
- 102100034608 Angiopoietin-2 Human genes 0.000 description 2
- 108010048036 Angiopoietin-2 Proteins 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000005548 Hexokinase Human genes 0.000 description 2
- 108700040460 Hexokinases Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 108010049175 N-substituted Glycines Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000000536 PPAR gamma Human genes 0.000 description 2
- 108091008767 PPARγ2 Proteins 0.000 description 2
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 2
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 2
- 101710170720 Prolyl hydroxylase EGLN3 Proteins 0.000 description 2
- 102100037247 Prolyl hydroxylase EGLN3 Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108091006296 SLC2A1 Proteins 0.000 description 2
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000002903 Thalassemia Diseases 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- MDWGKWCOAAEQCW-UHFFFAOYSA-N [2-chloro-1-(2-methoxyethoxymethyl)benzimidazol-5-yl]methanol Chemical compound OCC1=CC=C2N(COCCOC)C(Cl)=NC2=C1 MDWGKWCOAAEQCW-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000027746 artery morphogenesis Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- CPEKAXYCDKETEN-UHFFFAOYSA-N benzoyl isothiocyanate Chemical compound S=C=NC(=O)C1=CC=CC=C1 CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-YZRHJBSPSA-N butanedioic acid Chemical compound OC(=O)CC[14C](O)=O KDYFGRWQOYBRFD-YZRHJBSPSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000010437 erythropoiesis Effects 0.000 description 2
- 125000001033 ether group Chemical group 0.000 description 2
- LGMDXRUQAPBLKE-UHFFFAOYSA-N ethyl 1-(1h-imidazo[4,5-b]quinoxalin-2-yl)pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=NC3=CC=CC=C3N=C2N1 LGMDXRUQAPBLKE-UHFFFAOYSA-N 0.000 description 2
- OOCUXZDIMUIQGO-UHFFFAOYSA-N ethyl 1-(4-bromo-5,6-dichloro-1h-benzimidazol-2-yl)pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=C(Br)C(Cl)=C(Cl)C=C2N1 OOCUXZDIMUIQGO-UHFFFAOYSA-N 0.000 description 2
- ZTJWVQIWAKSYJN-UHFFFAOYSA-N ethyl 1-(4-bromo-6-fluoro-1h-benzimidazol-2-yl)pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=C(Br)C=C(F)C=C2N1 ZTJWVQIWAKSYJN-UHFFFAOYSA-N 0.000 description 2
- PJCBGMHCAJNIGB-UHFFFAOYSA-N ethyl 1-(4-chloro-1h-benzimidazol-2-yl)pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=C(Cl)C=CC=C2N1 PJCBGMHCAJNIGB-UHFFFAOYSA-N 0.000 description 2
- KUXLBGYSYVRAJB-UHFFFAOYSA-N ethyl 1-(5-chloro-6-ethylsulfinyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(Cl)=C(S(=O)CC)C=C2N1 KUXLBGYSYVRAJB-UHFFFAOYSA-N 0.000 description 2
- KLTORQQVLFQNKD-UHFFFAOYSA-N ethyl 1-(5-chloro-6-propan-2-ylsulfonyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(Cl)=C(S(=O)(=O)C(C)C)C=C2N1 KLTORQQVLFQNKD-UHFFFAOYSA-N 0.000 description 2
- ULRRQQVRJAYWSO-UHFFFAOYSA-N ethyl 1-(6-chloro-5-phenoxy-1h-benzimidazol-2-yl)pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(OC=3C=CC=CC=3)=C(Cl)C=C2N1 ULRRQQVRJAYWSO-UHFFFAOYSA-N 0.000 description 2
- CBMIJGDYBLZKEW-UHFFFAOYSA-N ethyl 1-[1-(2-methoxyethoxymethyl)-5-piperidin-1-yl-6-(trifluoromethoxy)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(N3CCCCC3)=C(OC(F)(F)F)C=C2N1COCCOC CBMIJGDYBLZKEW-UHFFFAOYSA-N 0.000 description 2
- YOOMCXMLLXYSGO-UHFFFAOYSA-N ethyl 1-[4,5,6-trichloro-1-(2-methoxyethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=C(Cl)C(Cl)=C(Cl)C=C2N1COCCOC YOOMCXMLLXYSGO-UHFFFAOYSA-N 0.000 description 2
- QOTWSJXLYCARQF-UHFFFAOYSA-N ethyl 1-[4-bromo-5,6-dichloro-1-(2-methoxyethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=C(Br)C(Cl)=C(Cl)C=C2N1COCCOC QOTWSJXLYCARQF-UHFFFAOYSA-N 0.000 description 2
- MFHUOQAYQICPOH-UHFFFAOYSA-N ethyl 1-[4-chloro-1-(2-methoxyethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=C(Cl)C=CC=C2N1COCCOC MFHUOQAYQICPOH-UHFFFAOYSA-N 0.000 description 2
- HFMKGKNVVZLIKK-UHFFFAOYSA-N ethyl 1-[5,6-dichloro-1-(dimethylsulfamoyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(Cl)=C(Cl)C=C2N1S(=O)(=O)N(C)C HFMKGKNVVZLIKK-UHFFFAOYSA-N 0.000 description 2
- GPZMEPFXEMLUMG-UHFFFAOYSA-N ethyl 1-[5-chloro-6-(4-chlorophenyl)sulfonyl-1h-benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(S(=O)(=O)C=3C=CC(Cl)=CC=3)=C(Cl)C=C2N1 GPZMEPFXEMLUMG-UHFFFAOYSA-N 0.000 description 2
- NFQWGESYXHYNKI-UHFFFAOYSA-N ethyl 1-[5-fluoro-1-(2-methoxyethoxymethyl)-4-methylbenzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=C(C)C(F)=CC=C2N1COCCOC NFQWGESYXHYNKI-UHFFFAOYSA-N 0.000 description 2
- JUPJVXACYJJGTR-UHFFFAOYSA-N ethyl 1-[5-tert-butylsulfanyl-6-chloro-1-(2-methoxyethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(SC(C)(C)C)=C(Cl)C=C2N1COCCOC JUPJVXACYJJGTR-UHFFFAOYSA-N 0.000 description 2
- JBKNDCAXIZUZDB-UHFFFAOYSA-N ethyl 1-[6-chloro-1-(2-methoxyethoxymethyl)-5-sulfanylbenzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(S)=C(Cl)C=C2N1COCCOC JBKNDCAXIZUZDB-UHFFFAOYSA-N 0.000 description 2
- ZYQCDJJLMDADAS-UHFFFAOYSA-N ethyl 1-[6-chloro-5-(3-methylphenyl)sulfanyl-1h-benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(SC=3C=C(C)C=CC=3)=C(Cl)C=C2N1 ZYQCDJJLMDADAS-UHFFFAOYSA-N 0.000 description 2
- VDIQTXYXWXWUDI-UHFFFAOYSA-N ethyl 1-[6-chloro-5-(ethylamino)-1-(2-methoxyethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound COCCOCN1C=2C=C(Cl)C(NCC)=CC=2N=C1N1C=C(C(=O)OCC)C=N1 VDIQTXYXWXWUDI-UHFFFAOYSA-N 0.000 description 2
- YTICPRYCICZFCP-UHFFFAOYSA-N ethyl 1-[6-ethylsulfonyl-1-(2-methoxyethoxymethyl)-5-(trifluoromethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(C(F)(F)F)=C(S(=O)(=O)CC)C=C2N1COCCOC YTICPRYCICZFCP-UHFFFAOYSA-N 0.000 description 2
- VWEGHFMNPRSLEF-UHFFFAOYSA-N ethyl 1-[n'-(2,6-dibromo-4-fluorophenyl)carbamimidoyl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C(=N)NC1=C(Br)C=C(F)C=C1Br VWEGHFMNPRSLEF-UHFFFAOYSA-N 0.000 description 2
- YNZOESCZYFRZPZ-UHFFFAOYSA-N ethyl 1-carbamimidoylpyrazole-4-carboxylate;hydrochloride Chemical compound Cl.CCOC(=O)C=1C=NN(C(N)=N)C=1 YNZOESCZYFRZPZ-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011737 fluorine Chemical group 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 150000002332 glycine derivatives Chemical class 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical class CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004066 metabolic change Effects 0.000 description 2
- KZVZYNPBVZXRRP-UHFFFAOYSA-N methyl 2-(4-ethoxycarbonylpyrazol-1-yl)-1-(2-methoxyethoxymethyl)benzimidazole-5-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(C(=O)OC)=CC=C2N1COCCOC KZVZYNPBVZXRRP-UHFFFAOYSA-N 0.000 description 2
- USTUYGJVCPXGJG-UHFFFAOYSA-N methyl 2-chloro-3h-benzimidazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2NC(Cl)=NC2=C1 USTUYGJVCPXGJG-UHFFFAOYSA-N 0.000 description 2
- KZBROPAHLBJQQC-UHFFFAOYSA-N methyl 2-oxo-1,3-dihydrobenzimidazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2NC(=O)NC2=C1 KZBROPAHLBJQQC-UHFFFAOYSA-N 0.000 description 2
- IOPLHGOSNCJOOO-UHFFFAOYSA-N methyl 3,4-diaminobenzoate Chemical compound COC(=O)C1=CC=C(N)C(N)=C1 IOPLHGOSNCJOOO-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 2
- NNAZZKHVQWGOTE-UHFFFAOYSA-N n-(4-chloro-3-cyanophenyl)acetamide Chemical compound CC(=O)NC1=CC=C(Cl)C(C#N)=C1 NNAZZKHVQWGOTE-UHFFFAOYSA-N 0.000 description 2
- SEGIVVWMYPSMNN-UHFFFAOYSA-N n-(4-chloro-5-cyano-2-nitrophenyl)acetamide Chemical compound CC(=O)NC1=CC(C#N)=C(Cl)C=C1[N+]([O-])=O SEGIVVWMYPSMNN-UHFFFAOYSA-N 0.000 description 2
- BLEZRQWUCHQBIN-UHFFFAOYSA-N n-[(2,6-dibromo-4-fluorophenyl)carbamothioyl]benzamide Chemical compound BrC1=CC(F)=CC(Br)=C1NC(=S)NC(=O)C1=CC=CC=C1 BLEZRQWUCHQBIN-UHFFFAOYSA-N 0.000 description 2
- VMUODWBZGNEBJN-UHFFFAOYSA-N n-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=C(C(F)(F)F)C(F)=C1 VMUODWBZGNEBJN-UHFFFAOYSA-N 0.000 description 2
- SANWVXNJRUHMBL-UHFFFAOYSA-N n-[5-fluoro-2-nitro-4-(trifluoromethyl)phenyl]acetamide Chemical compound CC(=O)NC1=CC(F)=C(C(F)(F)F)C=C1[N+]([O-])=O SANWVXNJRUHMBL-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001023 pro-angiogenic effect Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- GUOVPUQZTOCQCJ-UHFFFAOYSA-M sodium;1-hydroxy-2-morpholin-4-ylethanesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C(O)CN1CCOCC1 GUOVPUQZTOCQCJ-UHFFFAOYSA-M 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 229960005137 succinic acid Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 150000003585 thioureas Chemical class 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 230000004862 vasculogenesis Effects 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- LJZYEPXPMRRXTA-UHFFFAOYSA-N (2,4,6-trimethylphenyl)methanethiol Chemical group CC1=CC(C)=C(CS)C(C)=C1 LJZYEPXPMRRXTA-UHFFFAOYSA-N 0.000 description 1
- WWFIIZLHSNBNTC-UHFFFAOYSA-N (2-chlorophenyl)methanethiol Chemical group SCC1=CC=CC=C1Cl WWFIIZLHSNBNTC-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JKIGHOARKAIPJI-UHFFFAOYSA-N (3,4-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C(Cl)=C1 JKIGHOARKAIPJI-UHFFFAOYSA-N 0.000 description 1
- WFWQWTPAPNEOFE-UHFFFAOYSA-N (3-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(O)=C1 WFWQWTPAPNEOFE-UHFFFAOYSA-N 0.000 description 1
- WIJNYNBSPQMJGO-UHFFFAOYSA-N (3-phenylmethoxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(OCC=2C=CC=CC=2)=C1 WIJNYNBSPQMJGO-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- RKTRHMNWVZRZJQ-UHFFFAOYSA-N (4-fluorophenyl)methanethiol Chemical group FC1=CC=C(CS)C=C1 RKTRHMNWVZRZJQ-UHFFFAOYSA-N 0.000 description 1
- COIQUVGFTILYGA-UHFFFAOYSA-N (4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C=C1 COIQUVGFTILYGA-UHFFFAOYSA-N 0.000 description 1
- PTDVPWWJRCOIIO-UHFFFAOYSA-N (4-methoxyphenyl)methanethiol Chemical group COC1=CC=C(CS)C=C1 PTDVPWWJRCOIIO-UHFFFAOYSA-N 0.000 description 1
- DMJHEIDWSIAXCS-UHFFFAOYSA-N (4-phenylmethoxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OCC1=CC=CC=C1 DMJHEIDWSIAXCS-UHFFFAOYSA-N 0.000 description 1
- UIYKSYBJKIMANV-UHFFFAOYSA-N (4-tert-butylphenyl)methanethiol Chemical group CC(C)(C)C1=CC=C(CS)C=C1 UIYKSYBJKIMANV-UHFFFAOYSA-N 0.000 description 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- BINKZVSQCQHDCV-UHFFFAOYSA-N 1-(1h-benzimidazol-2-yl)-5-(2,5-dimethylpyrrol-1-yl)pyrazole-4-carboxylic acid Chemical compound CC1=CC=C(C)N1C1=C(C(O)=O)C=NN1C1=NC2=CC=CC=C2N1 BINKZVSQCQHDCV-UHFFFAOYSA-N 0.000 description 1
- XQEKFKOLSZZFIB-UHFFFAOYSA-N 1-(1h-benzimidazol-2-yl)-5-pyrrol-1-ylpyrazole-4-carboxylic acid Chemical compound OC(=O)C=1C=NN(C=2NC3=CC=CC=C3N=2)C=1N1C=CC=C1 XQEKFKOLSZZFIB-UHFFFAOYSA-N 0.000 description 1
- MAFPBDKXQKJAPP-UHFFFAOYSA-N 1-(1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC=CC=C2N1 MAFPBDKXQKJAPP-UHFFFAOYSA-N 0.000 description 1
- WRONRCMSXXZEMA-UHFFFAOYSA-N 1-(1h-benzo[f]benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC3=CC=CC=C3C=C2N1 WRONRCMSXXZEMA-UHFFFAOYSA-N 0.000 description 1
- GLHULOBKCAPXME-UHFFFAOYSA-N 1-(1h-imidazo[4,5-b]pyrazin-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=NC=CN=C2N1 GLHULOBKCAPXME-UHFFFAOYSA-N 0.000 description 1
- OGBAFCDGQKQFKA-UHFFFAOYSA-N 1-(3h-benzo[e]benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C(N1)=NC2=C1C=CC1=CC=CC=C21 OGBAFCDGQKQFKA-UHFFFAOYSA-N 0.000 description 1
- PHMGCYYPEIIVLX-UHFFFAOYSA-N 1-(4,5,6-trifluoro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=C(F)C(F)=C(F)C=C2N1 PHMGCYYPEIIVLX-UHFFFAOYSA-N 0.000 description 1
- QVBKGNDMZGHGIN-UHFFFAOYSA-N 1-(4,5-difluoro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=C(F)C(F)=CC=C2N1 QVBKGNDMZGHGIN-UHFFFAOYSA-N 0.000 description 1
- IDCRFLDBLINYPI-UHFFFAOYSA-N 1-(4,5-dimethyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C2=C(C)C(C)=CC=C2NC=1N1C=C(C(O)=O)C=N1 IDCRFLDBLINYPI-UHFFFAOYSA-N 0.000 description 1
- YNLXCKHHDSOZNS-UHFFFAOYSA-N 1-(4,6-dichloro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=C(Cl)C=C(Cl)C=C2N1 YNLXCKHHDSOZNS-UHFFFAOYSA-N 0.000 description 1
- JWAJEIQASIWFMK-UHFFFAOYSA-N 1-(4,6-difluoro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=C(F)C=C(F)C=C2N1 JWAJEIQASIWFMK-UHFFFAOYSA-N 0.000 description 1
- JVRZFXXLCMLIKS-UHFFFAOYSA-N 1-(4-bromo-5,6-difluoro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=C(Br)C(F)=C(F)C=C2N1 JVRZFXXLCMLIKS-UHFFFAOYSA-N 0.000 description 1
- AXDWQDJCMSDGAR-UHFFFAOYSA-N 1-(4-bromo-6-chloro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=C(Br)C=C(Cl)C=C2N1 AXDWQDJCMSDGAR-UHFFFAOYSA-N 0.000 description 1
- NVFCWZMPKKRQTO-UHFFFAOYSA-N 1-(4-fluoro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=C(F)C=CC=C2N1 NVFCWZMPKKRQTO-UHFFFAOYSA-N 0.000 description 1
- MRGBLKZOJNDKST-UHFFFAOYSA-N 1-(5,6-dichloro-1h-benzimidazol-2-yl)-3,5-dimethylpyrazole-4-carboxylic acid Chemical compound CC1=C(C(O)=O)C(C)=NN1C1=NC2=CC(Cl)=C(Cl)C=C2N1 MRGBLKZOJNDKST-UHFFFAOYSA-N 0.000 description 1
- DZQCTFTXFPTHOR-UHFFFAOYSA-N 1-(5,6-dichloro-1h-benzimidazol-2-yl)-3-(trifluoromethyl)pyrazole-4-carboxylic acid Chemical compound N1=C(C(F)(F)F)C(C(=O)O)=CN1C1=NC2=CC(Cl)=C(Cl)C=C2N1 DZQCTFTXFPTHOR-UHFFFAOYSA-N 0.000 description 1
- SAEOLIXSQGYPGH-UHFFFAOYSA-N 1-(5,6-difluoro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(F)=C(F)C=C2N1 SAEOLIXSQGYPGH-UHFFFAOYSA-N 0.000 description 1
- WKUVEIZDEMZQJO-UHFFFAOYSA-N 1-(5,6-dimethoxy-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(OC)C(OC)=CC=2N=C1N1C=C(C(O)=O)C=N1 WKUVEIZDEMZQJO-UHFFFAOYSA-N 0.000 description 1
- GFKKHYKYZJMBQV-UHFFFAOYSA-N 1-(5,6-dimethyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(C)C(C)=CC=2N=C1N1C=C(C(O)=O)C=N1 GFKKHYKYZJMBQV-UHFFFAOYSA-N 0.000 description 1
- FDXPRMJYZXGFGA-UHFFFAOYSA-N 1-(5-benzamido-6-chloro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(NC(=O)C=3C=CC=CC=3)=C(Cl)C=C2N1 FDXPRMJYZXGFGA-UHFFFAOYSA-N 0.000 description 1
- CTEUHDOUSFPOFC-UHFFFAOYSA-N 1-(5-bromo-7-methyl-3h-imidazo[4,5-f]quinolin-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(Br)C3=NC(C)=CC=C3C=2NC=1N1C=C(C(O)=O)C=N1 CTEUHDOUSFPOFC-UHFFFAOYSA-N 0.000 description 1
- VOINEICHGDKMIS-UHFFFAOYSA-N 1-(5-chloro-6-fluoro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(Cl)=C(F)C=C2N1 VOINEICHGDKMIS-UHFFFAOYSA-N 0.000 description 1
- UNJGGNCSTFQSJV-UHFFFAOYSA-N 1-(5-chloro-6-methylsulfonyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(Cl)C(S(=O)(=O)C)=CC=2NC=1N1C=C(C(O)=O)C=N1 UNJGGNCSTFQSJV-UHFFFAOYSA-N 0.000 description 1
- DWLUYDZJPSLTRR-UHFFFAOYSA-N 1-(5-ethoxy-6-fluoro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(F)C(OCC)=CC=2NC=1N1C=C(C(O)=O)C=N1 DWLUYDZJPSLTRR-UHFFFAOYSA-N 0.000 description 1
- WPCKSRDVPCIEKG-UHFFFAOYSA-N 1-(5-ethylsulfanyl-6-fluoro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(F)C(SCC)=CC=2N=C1N1C=C(C(O)=O)C=N1 WPCKSRDVPCIEKG-UHFFFAOYSA-N 0.000 description 1
- HJIRKOJDKSOBGW-UHFFFAOYSA-N 1-(5-ethylsulfonyl-6-fluoro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(F)C(S(=O)(=O)CC)=CC=2N=C1N1C=C(C(O)=O)C=N1 HJIRKOJDKSOBGW-UHFFFAOYSA-N 0.000 description 1
- CPZAKLJLASPJHU-UHFFFAOYSA-N 1-(6,7-dichloro-1h-imidazo[4,5-b]quinoxalin-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=NC3=CC(Cl)=C(Cl)C=C3N=C2N1 CPZAKLJLASPJHU-UHFFFAOYSA-N 0.000 description 1
- MXHYPHXAWAFGQS-UHFFFAOYSA-N 1-(6-benzylsulfonyl-5-chloro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)CC=3C=CC=CC=3)=C(Cl)C=C2N1 MXHYPHXAWAFGQS-UHFFFAOYSA-N 0.000 description 1
- SVEWJLPIGSFPEA-UHFFFAOYSA-N 1-(6-bromo-1h-benzimidazol-2-yl)-3,5-dimethylpyrazole-4-carboxylic acid Chemical compound CC1=C(C(O)=O)C(C)=NN1C1=NC2=CC(Br)=CC=C2N1 SVEWJLPIGSFPEA-UHFFFAOYSA-N 0.000 description 1
- LNIQCKCOYHXAKL-UHFFFAOYSA-N 1-(6-bromo-1h-benzimidazol-2-yl)-3-(trifluoromethyl)pyrazole-4-carboxylic acid Chemical compound N1=C(C(F)(F)F)C(C(=O)O)=CN1C1=NC2=CC(Br)=CC=C2N1 LNIQCKCOYHXAKL-UHFFFAOYSA-N 0.000 description 1
- YWPJDMRWXCDCMU-UHFFFAOYSA-N 1-(6-bromo-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(Br)=CC=C2N1 YWPJDMRWXCDCMU-UHFFFAOYSA-N 0.000 description 1
- KURVVPBGVUWXEB-UHFFFAOYSA-N 1-(6-bromo-4,5-dimethyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N1C2=C(C)C(C)=C(Br)C=C2N=C1N1C=C(C(O)=O)C=N1 KURVVPBGVUWXEB-UHFFFAOYSA-N 0.000 description 1
- IXJITVGDRQWPOC-UHFFFAOYSA-N 1-(6-bromo-4-methyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N1C=2C(C)=CC(Br)=CC=2N=C1N1C=C(C(O)=O)C=N1 IXJITVGDRQWPOC-UHFFFAOYSA-N 0.000 description 1
- QBOVGEJCROWRIO-UHFFFAOYSA-N 1-(6-chloro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(Cl)=CC=C2N1 QBOVGEJCROWRIO-UHFFFAOYSA-N 0.000 description 1
- WMLNUBUDPSCVFB-UHFFFAOYSA-N 1-(6-chloro-4-methyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C=2C(C)=CC(Cl)=CC=2NC=1N1C=C(C(O)=O)C=N1 WMLNUBUDPSCVFB-UHFFFAOYSA-N 0.000 description 1
- JGENBDBOSGKRJH-UHFFFAOYSA-N 1-(6-chloro-5-cyano-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C#N)=C(Cl)C=C2N1 JGENBDBOSGKRJH-UHFFFAOYSA-N 0.000 description 1
- PBBFJIMWSOYJME-UHFFFAOYSA-N 1-(6-chloro-5-ethylsulfanyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(Cl)C(SCC)=CC=2NC=1N1C=C(C(O)=O)C=N1 PBBFJIMWSOYJME-UHFFFAOYSA-N 0.000 description 1
- YGOWYGOQHLZKRU-UHFFFAOYSA-N 1-(6-chloro-5-methylsulfanyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(Cl)C(SC)=CC=2NC=1N1C=C(C(O)=O)C=N1 YGOWYGOQHLZKRU-UHFFFAOYSA-N 0.000 description 1
- ZKVZEDDQOJUUNP-UHFFFAOYSA-N 1-(6-chloro-5-nitro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC([N+]([O-])=O)=C(Cl)C=C2N1 ZKVZEDDQOJUUNP-UHFFFAOYSA-N 0.000 description 1
- KJNOWHUNCHHZAA-UHFFFAOYSA-N 1-(6-chloro-5-phenylsulfanyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SC=3C=CC=CC=3)=C(Cl)C=C2N1 KJNOWHUNCHHZAA-UHFFFAOYSA-N 0.000 description 1
- JKYUSIUGMVPBSI-UHFFFAOYSA-N 1-(6-chloro-5-propan-2-ylsulfanyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(Cl)C(SC(C)C)=CC=2NC=1N1C=C(C(O)=O)C=N1 JKYUSIUGMVPBSI-UHFFFAOYSA-N 0.000 description 1
- XXJSRLOPUVBIDH-UHFFFAOYSA-N 1-(6-chloro-5-propylsulfanyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(Cl)C(SCCC)=CC=2NC=1N1C=C(C(O)=O)C=N1 XXJSRLOPUVBIDH-UHFFFAOYSA-N 0.000 description 1
- CUUNRCLQYYHUAQ-UHFFFAOYSA-N 1-(6-chloro-5-pyrrolidin-1-yl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(N3CCCC3)=C(Cl)C=C2N1 CUUNRCLQYYHUAQ-UHFFFAOYSA-N 0.000 description 1
- MARXCUJJLZCPGU-UHFFFAOYSA-N 1-(6-chloro-7h-purin-8-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=C(Cl)N=CN=C2N1 MARXCUJJLZCPGU-UHFFFAOYSA-N 0.000 description 1
- BFYGBADEUCSFOB-UHFFFAOYSA-N 1-(6-fluoro-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(F)=CC=C2N1 BFYGBADEUCSFOB-UHFFFAOYSA-N 0.000 description 1
- LOCOMMWWLNSHDY-UHFFFAOYSA-N 1-(6-fluoro-5-methylsulfanyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(F)C(SC)=CC=2NC=1N1C=C(C(O)=O)C=N1 LOCOMMWWLNSHDY-UHFFFAOYSA-N 0.000 description 1
- ZQHCTSIRYPESFK-UHFFFAOYSA-N 1-(6-fluoro-5-methylsulfonyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(F)C(S(=O)(=O)C)=CC=2NC=1N1C=C(C(O)=O)C=N1 ZQHCTSIRYPESFK-UHFFFAOYSA-N 0.000 description 1
- RJJLKALZWDUECQ-UHFFFAOYSA-N 1-(6-fluoro-5-piperidin-1-yl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(F)=C(N3CCCCC3)C=C2N1 RJJLKALZWDUECQ-UHFFFAOYSA-N 0.000 description 1
- ZLVSUOSYSCPZOH-UHFFFAOYSA-N 1-(6-fluoro-5-propan-2-ylsulfanyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(F)C(SC(C)C)=CC=2N=C1N1C=C(C(O)=O)C=N1 ZLVSUOSYSCPZOH-UHFFFAOYSA-N 0.000 description 1
- QDQWAGODVIYVGJ-UHFFFAOYSA-N 1-(6-fluoro-5-propan-2-ylsulfonyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(F)C(S(=O)(=O)C(C)C)=CC=2N=C1N1C=C(C(O)=O)C=N1 QDQWAGODVIYVGJ-UHFFFAOYSA-N 0.000 description 1
- NDJLNONXSBHQRQ-UHFFFAOYSA-N 1-(6-fluoro-5-propylsulfonyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(F)C(S(=O)(=O)CCC)=CC=2N=C1N1C=C(C(O)=O)C=N1 NDJLNONXSBHQRQ-UHFFFAOYSA-N 0.000 description 1
- CBVUKTUATPEIOW-UHFFFAOYSA-N 1-(6-methoxy-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N=1C2=CC(OC)=CC=C2NC=1N1C=C(C(O)=O)C=N1 CBVUKTUATPEIOW-UHFFFAOYSA-N 0.000 description 1
- JPXQQMBXDSWDKE-UHFFFAOYSA-N 1-(6-methylsulfonyl-1h-benzimidazol-2-yl)pyrazole-4-carboxylic acid Chemical compound N1C2=CC(S(=O)(=O)C)=CC=C2N=C1N1C=C(C(O)=O)C=N1 JPXQQMBXDSWDKE-UHFFFAOYSA-N 0.000 description 1
- SWFFFUJOWAJJCH-UHFFFAOYSA-N 1-(bromomethyl)-2,4-bis(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(CBr)C(C(F)(F)F)=C1 SWFFFUJOWAJJCH-UHFFFAOYSA-N 0.000 description 1
- LZIYAIRGDHSVED-UHFFFAOYSA-N 1-(bromomethyl)-3-chlorobenzene Chemical compound ClC1=CC=CC(CBr)=C1 LZIYAIRGDHSVED-UHFFFAOYSA-N 0.000 description 1
- IKSNDOVDVVPSMA-UHFFFAOYSA-N 1-(bromomethyl)-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(CBr)C=C1 IKSNDOVDVVPSMA-UHFFFAOYSA-N 0.000 description 1
- KQNBRMUBPRGXSL-UHFFFAOYSA-N 1-(bromomethyl)-4-chlorobenzene Chemical compound ClC1=CC=C(CBr)C=C1 KQNBRMUBPRGXSL-UHFFFAOYSA-N 0.000 description 1
- WZRKSPFYXUXINF-UHFFFAOYSA-N 1-(bromomethyl)-4-methylbenzene Chemical compound CC1=CC=C(CBr)C=C1 WZRKSPFYXUXINF-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- PYWMNDHHEJYSFX-UHFFFAOYSA-N 1-[4-bromo-6-(trifluoromethoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(OC(F)(F)F)=CC(Br)=C2N1 PYWMNDHHEJYSFX-UHFFFAOYSA-N 0.000 description 1
- VVGRNDJKOJCXGU-UHFFFAOYSA-N 1-[4-bromo-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=C(Br)C=C(C(F)(F)F)C=C2N1 VVGRNDJKOJCXGU-UHFFFAOYSA-N 0.000 description 1
- XSYPEEZNSOWVAZ-UHFFFAOYSA-N 1-[4-chloro-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=C(Cl)C=C(C(F)(F)F)C=C2N1 XSYPEEZNSOWVAZ-UHFFFAOYSA-N 0.000 description 1
- DJPDAGMWFAKILD-UHFFFAOYSA-N 1-[5,6-bis(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C(F)(F)F)=C(C(F)(F)F)C=C2N1 DJPDAGMWFAKILD-UHFFFAOYSA-N 0.000 description 1
- GSABLVMUHJCSBR-UHFFFAOYSA-N 1-[5-(4-chlorophenoxy)-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(OC=3C=CC(Cl)=CC=3)=C(C(F)(F)F)C=C2N1 GSABLVMUHJCSBR-UHFFFAOYSA-N 0.000 description 1
- REEFDEAGHLHHID-UHFFFAOYSA-N 1-[5-(4-fluorophenoxy)-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(OC=3C=CC(F)=CC=3)=C(C(F)(F)F)C=C2N1 REEFDEAGHLHHID-UHFFFAOYSA-N 0.000 description 1
- BDLLVQXRSGPPSC-UHFFFAOYSA-N 1-[5-(4-methoxyphenyl)sulfanyl-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1SC(C(=C1)C(F)(F)F)=CC2=C1NC(N1N=CC(=C1)C(O)=O)=N2 BDLLVQXRSGPPSC-UHFFFAOYSA-N 0.000 description 1
- IUZFUIBUQSSUDM-UHFFFAOYSA-N 1-[5-(4-methoxyphenyl)sulfonyl-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C(C(=C1)C(F)(F)F)=CC2=C1NC(N1N=CC(=C1)C(O)=O)=N2 IUZFUIBUQSSUDM-UHFFFAOYSA-N 0.000 description 1
- VCDZTCLDWWVSBJ-UHFFFAOYSA-N 1-[5-(benzenesulfonamido)-6-chloro-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(NS(=O)(=O)C=3C=CC=CC=3)=C(Cl)C=C2N1 VCDZTCLDWWVSBJ-UHFFFAOYSA-N 0.000 description 1
- QRAXYELCUSRSGW-UHFFFAOYSA-N 1-[5-(benzenesulfonyl)-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)C=3C=CC=CC=3)=C(C(F)(F)F)C=C2N1 QRAXYELCUSRSGW-UHFFFAOYSA-N 0.000 description 1
- CKRMPWXLDXKKIO-UHFFFAOYSA-N 1-[5-[(4-tert-butylphenyl)methylsulfanyl]-6-chloro-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1CSC(C(=C1)Cl)=CC2=C1NC(N1N=CC(=C1)C(O)=O)=N2 CKRMPWXLDXKKIO-UHFFFAOYSA-N 0.000 description 1
- QLQQGZQCCAZKQR-UHFFFAOYSA-N 1-[5-[[2,4-bis(trifluoromethyl)phenyl]methylsulfanyl]-6-chloro-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SCC=3C(=CC(=CC=3)C(F)(F)F)C(F)(F)F)=C(Cl)C=C2N1 QLQQGZQCCAZKQR-UHFFFAOYSA-N 0.000 description 1
- AQLFXKWIEVXXIO-UHFFFAOYSA-N 1-[5-chloro-6-(2-phenylethylsulfonyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)CCC=3C=CC=CC=3)=C(Cl)C=C2N1 AQLFXKWIEVXXIO-UHFFFAOYSA-N 0.000 description 1
- ABPHDCKNFBLFRP-UHFFFAOYSA-N 1-[5-chloro-6-(3,4-dichlorophenyl)sulfonyl-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)C=3C=C(Cl)C(Cl)=CC=3)=C(Cl)C=C2N1 ABPHDCKNFBLFRP-UHFFFAOYSA-N 0.000 description 1
- UHMTWWLXFWILIE-UHFFFAOYSA-N 1-[5-chloro-6-(3-methoxyphenyl)sulfonyl-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound COC1=CC=CC(S(=O)(=O)C=2C(=CC=3NC(=NC=3C=2)N2N=CC(=C2)C(O)=O)Cl)=C1 UHMTWWLXFWILIE-UHFFFAOYSA-N 0.000 description 1
- XBAYTOVBCPUCRJ-UHFFFAOYSA-N 1-[5-chloro-6-(4-methoxyphenyl)sulfonyl-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C(C(=C1)Cl)=CC2=C1NC(N1N=CC(=C1)C(O)=O)=N2 XBAYTOVBCPUCRJ-UHFFFAOYSA-N 0.000 description 1
- YSNILTADUBOOHX-UHFFFAOYSA-N 1-[5-chloro-6-(cyclohexylmethylsulfonyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)CC3CCCCC3)=C(Cl)C=C2N1 YSNILTADUBOOHX-UHFFFAOYSA-N 0.000 description 1
- UIQBWHCJBOIWNK-UHFFFAOYSA-N 1-[5-chloro-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C(F)(F)F)=C(Cl)C=C2N1 UIQBWHCJBOIWNK-UHFFFAOYSA-N 0.000 description 1
- GPVMDBWYXDAPDY-UHFFFAOYSA-N 1-[5-chloro-6-[(2,6-dichlorophenyl)methylsulfonyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3Cl)Cl)=C(Cl)C=C2N1 GPVMDBWYXDAPDY-UHFFFAOYSA-N 0.000 description 1
- CSPMKZGGGZEPAT-UHFFFAOYSA-N 1-[5-chloro-6-[(2-chlorophenyl)methylsulfonyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)CC=3C(=CC=CC=3)Cl)=C(Cl)C=C2N1 CSPMKZGGGZEPAT-UHFFFAOYSA-N 0.000 description 1
- KPRKBCSLUNQLJC-UHFFFAOYSA-N 1-[5-chloro-6-[(3,4-dichlorophenyl)methylsulfonyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)CC=3C=C(Cl)C(Cl)=CC=3)=C(Cl)C=C2N1 KPRKBCSLUNQLJC-UHFFFAOYSA-N 0.000 description 1
- LXMOULRLTWQJFV-UHFFFAOYSA-N 1-[5-chloro-6-[(3-chlorophenyl)methylsulfonyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)CC=3C=C(Cl)C=CC=3)=C(Cl)C=C2N1 LXMOULRLTWQJFV-UHFFFAOYSA-N 0.000 description 1
- YDKTXLMBLOTICX-UHFFFAOYSA-N 1-[5-chloro-6-[(4-chlorophenyl)methylsulfonyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)CC=3C=CC(Cl)=CC=3)=C(Cl)C=C2N1 YDKTXLMBLOTICX-UHFFFAOYSA-N 0.000 description 1
- MNUKELXBBCDZBJ-UHFFFAOYSA-N 1-[5-chloro-6-[(4-fluorophenyl)methylsulfonyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)CC=3C=CC(F)=CC=3)=C(Cl)C=C2N1 MNUKELXBBCDZBJ-UHFFFAOYSA-N 0.000 description 1
- TUNFONZLEMUBTD-UHFFFAOYSA-N 1-[5-chloro-6-[(4-methylphenyl)methylsulfonyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=CC(C)=CC=C1CS(=O)(=O)C(C(=C1)Cl)=CC2=C1NC(N1N=CC(=C1)C(O)=O)=N2 TUNFONZLEMUBTD-UHFFFAOYSA-N 0.000 description 1
- VAGRXEYATXSNCW-UHFFFAOYSA-N 1-[5-chloro-6-[[4-(2-cyanophenyl)phenyl]methylsulfonyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C#N)=C(Cl)C=C2N1 VAGRXEYATXSNCW-UHFFFAOYSA-N 0.000 description 1
- WRJXMSGXSPNEJU-UHFFFAOYSA-N 1-[5-chloro-6-[[4-(trifluoromethyl)phenyl]methylsulfonyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)CC=3C=CC(=CC=3)C(F)(F)F)=C(Cl)C=C2N1 WRJXMSGXSPNEJU-UHFFFAOYSA-N 0.000 description 1
- IGDVPJKNAYDWQK-UHFFFAOYSA-N 1-[5-ethylsulfanyl-6-(trifluoromethoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(OC(F)(F)F)C(SCC)=CC=2N=C1N1C=C(C(O)=O)C=N1 IGDVPJKNAYDWQK-UHFFFAOYSA-N 0.000 description 1
- LPODKJNVHGNQRX-UHFFFAOYSA-N 1-[5-ethylsulfonyl-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(C(F)(F)F)C(S(=O)(=O)CC)=CC=2N=C1N1C=C(C(O)=O)C=N1 LPODKJNVHGNQRX-UHFFFAOYSA-N 0.000 description 1
- OTYMTMJAFGWNSU-UHFFFAOYSA-N 1-[5-fluoro-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C(F)(F)F)=C(F)C=C2N1 OTYMTMJAFGWNSU-UHFFFAOYSA-N 0.000 description 1
- BXZCESWOJHPUAG-UHFFFAOYSA-N 1-[5-methylsulfanyl-6-(trifluoromethoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(OC(F)(F)F)C(SC)=CC=2NC=1N1C=C(C(O)=O)C=N1 BXZCESWOJHPUAG-UHFFFAOYSA-N 0.000 description 1
- FWMWXMSBKFNMJF-UHFFFAOYSA-N 1-[5-methylsulfonyl-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(C(F)(F)F)C(S(=O)(=O)C)=CC=2NC=1N1C=C(C(O)=O)C=N1 FWMWXMSBKFNMJF-UHFFFAOYSA-N 0.000 description 1
- YJCUECDMBKMFIJ-UHFFFAOYSA-N 1-[5-phenoxy-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(OC=3C=CC=CC=3)=C(C(F)(F)F)C=C2N1 YJCUECDMBKMFIJ-UHFFFAOYSA-N 0.000 description 1
- ISRIAFIUWWBKKQ-UHFFFAOYSA-N 1-[5-phenylsulfanyl-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SC=3C=CC=CC=3)=C(C(F)(F)F)C=C2N1 ISRIAFIUWWBKKQ-UHFFFAOYSA-N 0.000 description 1
- VZLHNDDNKTVNIM-UHFFFAOYSA-N 1-[5-propan-2-ylsulfanyl-6-(trifluoromethoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(OC(F)(F)F)C(SC(C)C)=CC=2NC=1N1C=C(C(O)=O)C=N1 VZLHNDDNKTVNIM-UHFFFAOYSA-N 0.000 description 1
- YEQWKRMLXIFOHN-UHFFFAOYSA-N 1-[5-propan-2-ylsulfanyl-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(C(F)(F)F)C(SC(C)C)=CC=2NC=1N1C=C(C(O)=O)C=N1 YEQWKRMLXIFOHN-UHFFFAOYSA-N 0.000 description 1
- XXDAMRZVFAHDMA-UHFFFAOYSA-N 1-[5-propan-2-ylsulfonyl-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(C(F)(F)F)C(S(=O)(=O)C(C)C)=CC=2NC=1N1C=C(C(O)=O)C=N1 XXDAMRZVFAHDMA-UHFFFAOYSA-N 0.000 description 1
- UACBSXIBJIYKLH-UHFFFAOYSA-N 1-[5-propylsulfanyl-6-(trifluoromethoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(OC(F)(F)F)C(SCCC)=CC=2NC=1N1C=C(C(O)=O)C=N1 UACBSXIBJIYKLH-UHFFFAOYSA-N 0.000 description 1
- WTYHNFBGWPRYQY-UHFFFAOYSA-N 1-[5-propylsulfonyl-6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(C(F)(F)F)C(S(=O)(=O)CCC)=CC=2NC=1N1C=C(C(O)=O)C=N1 WTYHNFBGWPRYQY-UHFFFAOYSA-N 0.000 description 1
- VWSLIIMQMGRNHC-UHFFFAOYSA-N 1-[6-(3,4-dichlorophenyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C=3C=C(Cl)C(Cl)=CC=3)=CC=C2N1 VWSLIIMQMGRNHC-UHFFFAOYSA-N 0.000 description 1
- LZXBZILJESOINQ-UHFFFAOYSA-N 1-[6-(3-hydroxyphenyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C=3C=C(O)C=CC=3)=CC=C2N1 LZXBZILJESOINQ-UHFFFAOYSA-N 0.000 description 1
- OULCSSGZLYIVFI-UHFFFAOYSA-N 1-[6-(3-phenylmethoxyphenyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C=3C=C(OCC=4C=CC=CC=4)C=CC=3)=CC=C2N1 OULCSSGZLYIVFI-UHFFFAOYSA-N 0.000 description 1
- KSIGSHIRKVLPPA-UHFFFAOYSA-N 1-[6-(4-chlorophenoxy)-5-(trifluoromethoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(OC=3C=CC(Cl)=CC=3)=C(OC(F)(F)F)C=C2N1 KSIGSHIRKVLPPA-UHFFFAOYSA-N 0.000 description 1
- JBMYAXSJYOPHHF-UHFFFAOYSA-N 1-[6-(4-hydroxyphenyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C=3C=CC(O)=CC=3)=CC=C2N1 JBMYAXSJYOPHHF-UHFFFAOYSA-N 0.000 description 1
- MBIQKDSNZYMVGA-UHFFFAOYSA-N 1-[6-(4-phenylmethoxyphenyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C=3C=CC(OCC=4C=CC=CC=4)=CC=3)=CC=C2N1 MBIQKDSNZYMVGA-UHFFFAOYSA-N 0.000 description 1
- NUDPIBNRMLFVRZ-UHFFFAOYSA-N 1-[6-(benzenesulfinyl)-5-chloro-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)C=3C=CC=CC=3)=C(Cl)C=C2N1 NUDPIBNRMLFVRZ-UHFFFAOYSA-N 0.000 description 1
- OKGFFXCGIOKKBL-UHFFFAOYSA-N 1-[6-(benzenesulfonyl)-5-chloro-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)C=3C=CC=CC=3)=C(Cl)C=C2N1 OKGFFXCGIOKKBL-UHFFFAOYSA-N 0.000 description 1
- OZWAGVHXUBLJHH-UHFFFAOYSA-N 1-[6-(benzylcarbamoyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C(=O)NCC=3C=CC=CC=3)=CC=C2N1 OZWAGVHXUBLJHH-UHFFFAOYSA-N 0.000 description 1
- QBFMXRKVCFXSSV-UHFFFAOYSA-N 1-[6-(morpholin-4-ylcarbamoyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C(=O)NN3CCOCC3)=CC=C2N1 QBFMXRKVCFXSSV-UHFFFAOYSA-N 0.000 description 1
- GYUSYTTYVRWNIY-UHFFFAOYSA-N 1-[6-(trifluoromethoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(OC(F)(F)F)=CC=C2N1 GYUSYTTYVRWNIY-UHFFFAOYSA-N 0.000 description 1
- FEOYPRRUCRESLL-UHFFFAOYSA-N 1-[6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C(F)(F)F)=CC=C2N1 FEOYPRRUCRESLL-UHFFFAOYSA-N 0.000 description 1
- NKBWQOWGEQSAGN-UHFFFAOYSA-N 1-[6-[3-(trifluoromethyl)phenyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C=3C=C(C=CC=3)C(F)(F)F)=CC=C2N1 NKBWQOWGEQSAGN-UHFFFAOYSA-N 0.000 description 1
- SIMRQEFGUINMMN-UHFFFAOYSA-N 1-[6-[3-[(2-chlorophenyl)methoxy]phenyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C=3C=C(OCC=4C(=CC=CC=4)Cl)C=CC=3)=CC=C2N1 SIMRQEFGUINMMN-UHFFFAOYSA-N 0.000 description 1
- BHBKLZGMWFTEBL-UHFFFAOYSA-N 1-[6-[3-[(4-chlorophenyl)methoxy]phenyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(C=3C=C(OCC=4C=CC(Cl)=CC=4)C=CC=3)=CC=C2N1 BHBKLZGMWFTEBL-UHFFFAOYSA-N 0.000 description 1
- DWINTOSYWDNYGR-UHFFFAOYSA-N 1-[6-[[2,4-bis(trifluoromethyl)phenyl]methylsulfonyl]-5-chloro-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(S(=O)(=O)CC=3C(=CC(=CC=3)C(F)(F)F)C(F)(F)F)=C(Cl)C=C2N1 DWINTOSYWDNYGR-UHFFFAOYSA-N 0.000 description 1
- WMMQOOJZEOAYGN-UHFFFAOYSA-N 1-[6-chloro-1-(2-methoxyethoxymethyl)-5-(2-phenylethylsulfanyl)benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound ClC=1C(=CC2=C(N(C(=N2)N2N=CC(=C2)C(=O)O)COCCOC)C=1)SCCC1=CC=CC=C1 WMMQOOJZEOAYGN-UHFFFAOYSA-N 0.000 description 1
- CJBYMOBOCJRTIH-UHFFFAOYSA-N 1-[6-chloro-1-(2-methoxyethoxymethyl)-5-[(2-nitrophenyl)disulfanyl]benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound ClC=1C(=CC2=C(N(C(=N2)N2N=CC(=C2)C(=O)O)COCCOC)C=1)SSC1=C(C=CC=C1)[N+](=O)[O-] CJBYMOBOCJRTIH-UHFFFAOYSA-N 0.000 description 1
- XFYOZSNTJDYZAB-UHFFFAOYSA-N 1-[6-chloro-1-(2-methoxyethoxymethyl)-5-phenylsulfanylbenzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound ClC=1C(=CC2=C(N(C(=N2)N2N=CC(=C2)C(=O)O)COCCOC)C=1)SC1=CC=CC=C1 XFYOZSNTJDYZAB-UHFFFAOYSA-N 0.000 description 1
- OFEQYQLJIVKGNB-UHFFFAOYSA-N 1-[6-chloro-1-(2-methoxyethoxymethyl)-5-sulfanylbenzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical group ClC=1C(=CC2=C(N(C(=N2)N2N=CC(=C2)C(=O)O)COCCOC)C=1)S OFEQYQLJIVKGNB-UHFFFAOYSA-N 0.000 description 1
- FIIOTDKFBDJOKU-UHFFFAOYSA-N 1-[6-chloro-4-(trifluoromethyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(Cl)=CC(C(F)(F)F)=C2N1 FIIOTDKFBDJOKU-UHFFFAOYSA-N 0.000 description 1
- RQHQPDURKPFIGU-UHFFFAOYSA-N 1-[6-chloro-5-(2-morpholin-4-ylethylsulfanyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SCCN3CCOCC3)=C(Cl)C=C2N1 RQHQPDURKPFIGU-UHFFFAOYSA-N 0.000 description 1
- HMSYHETUFOFMCX-UHFFFAOYSA-N 1-[6-chloro-5-(2-phenylethylsulfanyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SCCC=3C=CC=CC=3)=C(Cl)C=C2N1 HMSYHETUFOFMCX-UHFFFAOYSA-N 0.000 description 1
- DGVSUCGZFPIXOP-UHFFFAOYSA-N 1-[6-chloro-5-(3,4-dichlorophenyl)sulfanyl-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SC=3C=C(Cl)C(Cl)=CC=3)=C(Cl)C=C2N1 DGVSUCGZFPIXOP-UHFFFAOYSA-N 0.000 description 1
- ANMLUJFFGSKGCR-UHFFFAOYSA-N 1-[6-chloro-5-(3-chloro-4-fluorophenoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(OC=3C=C(Cl)C(F)=CC=3)=C(Cl)C=C2N1 ANMLUJFFGSKGCR-UHFFFAOYSA-N 0.000 description 1
- SFNJNFUGARKFDI-UHFFFAOYSA-N 1-[6-chloro-5-(3-methoxyphenyl)sulfanyl-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound COC1=CC=CC(SC=2C(=CC=3NC(=NC=3C=2)N2N=CC(=C2)C(O)=O)Cl)=C1 SFNJNFUGARKFDI-UHFFFAOYSA-N 0.000 description 1
- DQAZYBWBWVTUHK-UHFFFAOYSA-N 1-[6-chloro-5-(4-chloro-2-fluorophenoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(OC=3C(=CC(Cl)=CC=3)F)=C(Cl)C=C2N1 DQAZYBWBWVTUHK-UHFFFAOYSA-N 0.000 description 1
- JFPSWBYJPQDBFC-UHFFFAOYSA-N 1-[6-chloro-5-(4-chlorophenoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(OC=3C=CC(Cl)=CC=3)=C(Cl)C=C2N1 JFPSWBYJPQDBFC-UHFFFAOYSA-N 0.000 description 1
- YQFNDLDBGUHUMW-UHFFFAOYSA-N 1-[6-chloro-5-(4-chlorophenyl)sulfanyl-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SC=3C=CC(Cl)=CC=3)=C(Cl)C=C2N1 YQFNDLDBGUHUMW-UHFFFAOYSA-N 0.000 description 1
- IKHYTXRXRQOKLI-UHFFFAOYSA-N 1-[6-chloro-5-(4-methoxyphenoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1OC(C(=C1)Cl)=CC2=C1NC(N1N=CC(=C1)C(O)=O)=N2 IKHYTXRXRQOKLI-UHFFFAOYSA-N 0.000 description 1
- VRZJEXIEWRHKCU-UHFFFAOYSA-N 1-[6-chloro-5-(4-methoxyphenyl)sulfanyl-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1SC(C(=C1)Cl)=CC2=C1NC(N1N=CC(=C1)C(O)=O)=N2 VRZJEXIEWRHKCU-UHFFFAOYSA-N 0.000 description 1
- WKNWZNPKYFPZCQ-UHFFFAOYSA-N 1-[6-chloro-5-(cyclohexylmethylsulfanyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SCC3CCCCC3)=C(Cl)C=C2N1 WKNWZNPKYFPZCQ-UHFFFAOYSA-N 0.000 description 1
- OIKDYCXOFGHAEO-UHFFFAOYSA-N 1-[6-chloro-5-(ethylsulfonylamino)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(Cl)C(NS(=O)(=O)CC)=CC=2N=C1N1C=C(C(O)=O)C=N1 OIKDYCXOFGHAEO-UHFFFAOYSA-N 0.000 description 1
- SFPSTOQMJJPERZ-UHFFFAOYSA-N 1-[6-chloro-5-(methanesulfonamido)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(Cl)C(NS(=O)(=O)C)=CC=2N=C1N1C=C(C(O)=O)C=N1 SFPSTOQMJJPERZ-UHFFFAOYSA-N 0.000 description 1
- VPMPQYJLACYCSP-UHFFFAOYSA-N 1-[6-chloro-5-(propanoylamino)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(Cl)C(NC(=O)CC)=CC=2N=C1N1C=C(C(O)=O)C=N1 VPMPQYJLACYCSP-UHFFFAOYSA-N 0.000 description 1
- MAXATKJHSMHTQS-UHFFFAOYSA-N 1-[6-chloro-5-(propylamino)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(Cl)C(NCCC)=CC=2N=C1N1C=C(C(O)=O)C=N1 MAXATKJHSMHTQS-UHFFFAOYSA-N 0.000 description 1
- PJYVDWCHPRMLCN-UHFFFAOYSA-N 1-[6-chloro-5-[(2,6-dichlorophenyl)methylsulfanyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SCC=3C(=CC=CC=3Cl)Cl)=C(Cl)C=C2N1 PJYVDWCHPRMLCN-UHFFFAOYSA-N 0.000 description 1
- QRZQGVINHVFENC-UHFFFAOYSA-N 1-[6-chloro-5-[(2-chlorophenyl)methylsulfanyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SCC=3C(=CC=CC=3)Cl)=C(Cl)C=C2N1 QRZQGVINHVFENC-UHFFFAOYSA-N 0.000 description 1
- WDSHHNRRPZKZFD-UHFFFAOYSA-N 1-[6-chloro-5-[(2-piperidin-1-ylacetyl)amino]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(NC(=O)CN3CCCCC3)=C(Cl)C=C2N1 WDSHHNRRPZKZFD-UHFFFAOYSA-N 0.000 description 1
- HTWYBWWAUZNYTQ-UHFFFAOYSA-N 1-[6-chloro-5-[(3,4-dichlorophenyl)methylsulfanyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SCC=3C=C(Cl)C(Cl)=CC=3)=C(Cl)C=C2N1 HTWYBWWAUZNYTQ-UHFFFAOYSA-N 0.000 description 1
- SGLTXWCJAGGOLD-UHFFFAOYSA-N 1-[6-chloro-5-[(3-chlorophenyl)methylsulfanyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SCC=3C=C(Cl)C=CC=3)=C(Cl)C=C2N1 SGLTXWCJAGGOLD-UHFFFAOYSA-N 0.000 description 1
- ARODGPQEJHJMNI-UHFFFAOYSA-N 1-[6-chloro-5-[(4-chlorophenyl)methylsulfanyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SCC=3C=CC(Cl)=CC=3)=C(Cl)C=C2N1 ARODGPQEJHJMNI-UHFFFAOYSA-N 0.000 description 1
- ZAKLAWDPZOLOCU-UHFFFAOYSA-N 1-[6-chloro-5-[(4-fluorophenyl)methylsulfanyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SCC=3C=CC(F)=CC=3)=C(Cl)C=C2N1 ZAKLAWDPZOLOCU-UHFFFAOYSA-N 0.000 description 1
- ZXXUARQQGDNEIV-UHFFFAOYSA-N 1-[6-chloro-5-[(4-methylphenyl)methylsulfanyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=CC(C)=CC=C1CSC(C(=C1)Cl)=CC2=C1NC(N1N=CC(=C1)C(O)=O)=N2 ZXXUARQQGDNEIV-UHFFFAOYSA-N 0.000 description 1
- AQFFETSDDHMLKC-UHFFFAOYSA-N 1-[6-chloro-5-[4-(trifluoromethoxy)phenoxy]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(OC=3C=CC(OC(F)(F)F)=CC=3)=C(Cl)C=C2N1 AQFFETSDDHMLKC-UHFFFAOYSA-N 0.000 description 1
- DDJVVJGNEZNBNR-UHFFFAOYSA-N 1-[6-chloro-5-[[4-(2-cyanophenyl)phenyl]methylsulfanyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SCC=3C=CC(=CC=3)C=3C(=CC=CC=3)C#N)=C(Cl)C=C2N1 DDJVVJGNEZNBNR-UHFFFAOYSA-N 0.000 description 1
- JYOCLJOXUYCWKD-UHFFFAOYSA-N 1-[6-chloro-5-[[4-(trifluoromethyl)phenyl]methylsulfanyl]-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(SCC=3C=CC(=CC=3)C(F)(F)F)=C(Cl)C=C2N1 JYOCLJOXUYCWKD-UHFFFAOYSA-N 0.000 description 1
- SAIIRXZKNDRTPQ-UHFFFAOYSA-N 1-[6-ethylsulfinyl-1-(2-methoxyethoxymethyl)-5-(trifluoromethyl)benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound CCS(=O)C1=C(C=C2N=C(N3C=C(C=N3)C(O)=O)N(COCCOC)C2=C1)C(F)(F)F SAIIRXZKNDRTPQ-UHFFFAOYSA-N 0.000 description 1
- WUXRPHJBNTVNEN-UHFFFAOYSA-N 1-[6-ethylsulfonyl-5-(trifluoromethoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N1C=2C=C(OC(F)(F)F)C(S(=O)(=O)CC)=CC=2N=C1N1C=C(C(O)=O)C=N1 WUXRPHJBNTVNEN-UHFFFAOYSA-N 0.000 description 1
- ZPXPIKXZUOSBAS-UHFFFAOYSA-N 1-[6-methylsulfonyl-5-(trifluoromethoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(OC(F)(F)F)C(S(=O)(=O)C)=CC=2NC=1N1C=C(C(O)=O)C=N1 ZPXPIKXZUOSBAS-UHFFFAOYSA-N 0.000 description 1
- BDKYAFARHCJZNH-UHFFFAOYSA-N 1-[6-phenoxy-5-(trifluoromethoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(OC=3C=CC=CC=3)=C(OC(F)(F)F)C=C2N1 BDKYAFARHCJZNH-UHFFFAOYSA-N 0.000 description 1
- RATRDOACURPKIK-UHFFFAOYSA-N 1-[6-propan-2-ylsulfonyl-5-(trifluoromethoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(OC(F)(F)F)C(S(=O)(=O)C(C)C)=CC=2NC=1N1C=C(C(O)=O)C=N1 RATRDOACURPKIK-UHFFFAOYSA-N 0.000 description 1
- ZLGJXFDVZKMFRM-UHFFFAOYSA-N 1-[6-propylsulfonyl-5-(trifluoromethoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound N=1C=2C=C(OC(F)(F)F)C(S(=O)(=O)CCC)=CC=2NC=1N1C=C(C(O)=O)C=N1 ZLGJXFDVZKMFRM-UHFFFAOYSA-N 0.000 description 1
- GJFYMYJYPARISZ-UHFFFAOYSA-N 1-bromo-2,5-difluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=C(Br)C=C1F GJFYMYJYPARISZ-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NJOHZFQUJCXUPR-UHFFFAOYSA-N 1h-benzimidazole;1h-pyrazole Chemical compound C=1C=NNC=1.C1=CC=C2NC=NC2=C1 NJOHZFQUJCXUPR-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- ILENVKAVEFKZSD-UHFFFAOYSA-N 2,3,4-trifluoro-6-nitroaniline Chemical compound NC1=C(F)C(F)=C(F)C=C1[N+]([O-])=O ILENVKAVEFKZSD-UHFFFAOYSA-N 0.000 description 1
- GQWLQHHUPKCOJH-UHFFFAOYSA-N 2,3,6,7-tetrachloroquinoxaline Chemical compound ClC1=C(Cl)N=C2C=C(Cl)C(Cl)=CC2=N1 GQWLQHHUPKCOJH-UHFFFAOYSA-N 0.000 description 1
- MLCNOCRGSBCAGH-UHFFFAOYSA-N 2,3-dichloropyrazine Chemical compound ClC1=NC=CN=C1Cl MLCNOCRGSBCAGH-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- OHWMGCCRVMEAIT-UHFFFAOYSA-N 2,4-dichloro-6-(trifluoromethyl)-1h-benzimidazole Chemical compound FC(F)(F)C1=CC(Cl)=C2N=C(Cl)NC2=C1 OHWMGCCRVMEAIT-UHFFFAOYSA-N 0.000 description 1
- IZEZAMILKKYOPW-UHFFFAOYSA-N 2,4-dichloro-6-nitroaniline Chemical compound NC1=C(Cl)C=C(Cl)C=C1[N+]([O-])=O IZEZAMILKKYOPW-UHFFFAOYSA-N 0.000 description 1
- ZDSRQBIJVZFVST-UHFFFAOYSA-N 2,5-dichloro-6-fluoro-1h-benzimidazole Chemical compound C1=C(Cl)C(F)=CC2=C1N=C(Cl)N2 ZDSRQBIJVZFVST-UHFFFAOYSA-N 0.000 description 1
- GFZAFGFWKQQMIV-UHFFFAOYSA-N 2,6-dichloro-1-(2-methoxyethoxymethyl)-5-nitrobenzimidazole Chemical compound [O-][N+](=O)C1=C(Cl)C=C2N(COCCOC)C(Cl)=NC2=C1 GFZAFGFWKQQMIV-UHFFFAOYSA-N 0.000 description 1
- LLIARSREYVCQHL-UHFFFAOYSA-N 2,6-dichloro-1h-benzimidazole Chemical compound C1=C(Cl)C=C2NC(Cl)=NC2=C1 LLIARSREYVCQHL-UHFFFAOYSA-N 0.000 description 1
- PDFGFQUSSYSWNI-UHFFFAOYSA-N 2-(bromomethyl)-1,3-dichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1CBr PDFGFQUSSYSWNI-UHFFFAOYSA-N 0.000 description 1
- LFFIEVAMVPCZNA-UHFFFAOYSA-N 2-[4-(bromomethyl)phenyl]benzonitrile Chemical group C1=CC(CBr)=CC=C1C1=CC=CC=C1C#N LFFIEVAMVPCZNA-UHFFFAOYSA-N 0.000 description 1
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical compound C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 description 1
- GDBFBFPCVDCVRM-UHFFFAOYSA-N 2-bromo-4,5-bis(trifluoromethyl)aniline Chemical compound NC1=CC(C(F)(F)F)=C(C(F)(F)F)C=C1Br GDBFBFPCVDCVRM-UHFFFAOYSA-N 0.000 description 1
- NPCIWMOFULRTDX-UHFFFAOYSA-N 2-bromo-4-chloro-6-nitroaniline Chemical compound NC1=C(Br)C=C(Cl)C=C1[N+]([O-])=O NPCIWMOFULRTDX-UHFFFAOYSA-N 0.000 description 1
- YIPBAKXAGVSSDF-UHFFFAOYSA-N 2-bromo-6-nitro-4-(trifluoromethoxy)aniline Chemical compound NC1=C(Br)C=C(OC(F)(F)F)C=C1[N+]([O-])=O YIPBAKXAGVSSDF-UHFFFAOYSA-N 0.000 description 1
- ZUZMWPRSGJTLHW-UHFFFAOYSA-N 2-bromo-6-nitro-4-(trifluoromethyl)aniline Chemical compound NC1=C(Br)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZUZMWPRSGJTLHW-UHFFFAOYSA-N 0.000 description 1
- VOCGJCDQHYQDCC-UHFFFAOYSA-N 2-chloro-1-(2-methoxyethoxymethyl)-5-(phenylmethoxymethyl)benzimidazole Chemical compound C=1C=C2N(COCCOC)C(Cl)=NC2=CC=1COCC1=CC=CC=C1 VOCGJCDQHYQDCC-UHFFFAOYSA-N 0.000 description 1
- WEEWAOPSVMOCGX-UHFFFAOYSA-N 2-chloro-1-(2-methoxyethoxymethyl)-n-phenylbenzimidazole-5-carboxamide Chemical compound C=1C=C2N(COCCOC)C(Cl)=NC2=CC=1C(=O)NC1=CC=CC=C1 WEEWAOPSVMOCGX-UHFFFAOYSA-N 0.000 description 1
- DPZKIQWKLGXXOG-UHFFFAOYSA-N 2-chloro-4,5-dimethyl-1h-benzimidazole Chemical compound CC1=CC=C2NC(Cl)=NC2=C1C DPZKIQWKLGXXOG-UHFFFAOYSA-N 0.000 description 1
- VFELEJMYVUPGEO-UHFFFAOYSA-N 2-chloro-5,6-difluoro-1h-benzimidazole Chemical compound C1=C(F)C(F)=CC2=C1NC(Cl)=N2 VFELEJMYVUPGEO-UHFFFAOYSA-N 0.000 description 1
- DVFRGNSDKWHLEZ-UHFFFAOYSA-N 2-chloro-5,6-dimethoxy-1h-benzimidazole Chemical compound C1=C(OC)C(OC)=CC2=C1NC(Cl)=N2 DVFRGNSDKWHLEZ-UHFFFAOYSA-N 0.000 description 1
- LTWREDHXPZYJOA-UHFFFAOYSA-N 2-chloro-5,6-dimethyl-1h-benzimidazole Chemical compound C1=C(C)C(C)=CC2=C1NC(Cl)=N2 LTWREDHXPZYJOA-UHFFFAOYSA-N 0.000 description 1
- DZCNHAOGTIIZDP-UHFFFAOYSA-N 2-chloro-6-(trifluoromethoxy)-1h-benzimidazole Chemical compound FC(F)(F)OC1=CC=C2NC(Cl)=NC2=C1 DZCNHAOGTIIZDP-UHFFFAOYSA-N 0.000 description 1
- CZQXWSPZVZKNRM-UHFFFAOYSA-N 2-chloro-6-(trifluoromethyl)-1h-benzimidazole Chemical compound FC(F)(F)C1=CC=C2N=C(Cl)NC2=C1 CZQXWSPZVZKNRM-UHFFFAOYSA-N 0.000 description 1
- FMDGYQOERIOABX-UHFFFAOYSA-N 2-chloro-6-methoxy-1h-benzimidazole Chemical compound COC1=CC=C2N=C(Cl)NC2=C1 FMDGYQOERIOABX-UHFFFAOYSA-N 0.000 description 1
- BHWHYGWMNMCXBA-UHFFFAOYSA-N 2-fluoro-6-nitroaniline Chemical compound NC1=C(F)C=CC=C1[N+]([O-])=O BHWHYGWMNMCXBA-UHFFFAOYSA-N 0.000 description 1
- HAFVMUGQWUCFSI-UHFFFAOYSA-N 2-nitro-5-propylsulfanyl-4-(trifluoromethyl)aniline Chemical compound CCCSC1=CC(N)=C([N+]([O-])=O)C=C1C(F)(F)F HAFVMUGQWUCFSI-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- ZMRFRBHYXOQLDK-UHFFFAOYSA-N 2-phenylethanethiol Chemical group SCCC1=CC=CC=C1 ZMRFRBHYXOQLDK-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HNJZDPKMMZXSKT-UHFFFAOYSA-N 3,4-dichlorobenzenethiol Chemical compound SC1=CC=C(Cl)C(Cl)=C1 HNJZDPKMMZXSKT-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- QGNXDMSEEPNKCF-UHFFFAOYSA-N 3,5-difluorobenzene-1,2-diamine Chemical compound NC1=CC(F)=CC(F)=C1N QGNXDMSEEPNKCF-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LKNCMGLEYLDJKY-UHFFFAOYSA-N 3-bromo-4,5-difluorobenzene-1,2-diamine Chemical compound NC1=CC(F)=C(F)C(Br)=C1N LKNCMGLEYLDJKY-UHFFFAOYSA-N 0.000 description 1
- ZQXLIXHVJVAPLW-UHFFFAOYSA-N 3-chloro-4-fluorophenol Chemical group OC1=CC=C(F)C(Cl)=C1 ZQXLIXHVJVAPLW-UHFFFAOYSA-N 0.000 description 1
- CRPZQUGQOPIFPQ-UHFFFAOYSA-N 3-fluoro-2-methyl-6-nitroaniline Chemical compound CC1=C(N)C([N+]([O-])=O)=CC=C1F CRPZQUGQOPIFPQ-UHFFFAOYSA-N 0.000 description 1
- CRRVZRDISHOQQL-UHFFFAOYSA-N 3-fluoro-4-(trifluoromethyl)aniline Chemical compound NC1=CC=C(C(F)(F)F)C(F)=C1 CRRVZRDISHOQQL-UHFFFAOYSA-N 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- QMVAZEHZOPDGHA-UHFFFAOYSA-N 3-methoxybenzenethiol Chemical compound COC1=CC=CC(S)=C1 QMVAZEHZOPDGHA-UHFFFAOYSA-N 0.000 description 1
- AUWPHGWEYHEAIG-UHFFFAOYSA-N 4,5,6-trichloropyrimidine Chemical compound ClC1=NC=NC(Cl)=C1Cl AUWPHGWEYHEAIG-UHFFFAOYSA-N 0.000 description 1
- IWFHBRFJOHTIPU-UHFFFAOYSA-N 4,5-dichlorobenzene-1,2-diamine Chemical compound NC1=CC(Cl)=C(Cl)C=C1N IWFHBRFJOHTIPU-UHFFFAOYSA-N 0.000 description 1
- JNEWVMQNHBQHHL-UHFFFAOYSA-N 4,5-difluoro-1h-benzimidazole Chemical compound FC1=CC=C2NC=NC2=C1F JNEWVMQNHBQHHL-UHFFFAOYSA-N 0.000 description 1
- CVMXEDZZSWLXPB-UHFFFAOYSA-N 4-(2-bromoethyl)morpholine Chemical compound BrCCN1CCOCC1 CVMXEDZZSWLXPB-UHFFFAOYSA-N 0.000 description 1
- XLWSBDFQAJXCQX-UHFFFAOYSA-N 4-(bromomethyl)-1,2-dichlorobenzene Chemical compound ClC1=CC=C(CBr)C=C1Cl XLWSBDFQAJXCQX-UHFFFAOYSA-N 0.000 description 1
- JHVNSRJPBXPZJU-UHFFFAOYSA-N 4-(trifluoromethoxy)benzenethiol Chemical group FC(F)(F)OC1=CC=C(S)C=C1 JHVNSRJPBXPZJU-UHFFFAOYSA-N 0.000 description 1
- WDRJNKMAZMEYOF-UHFFFAOYSA-N 4-(trifluoromethoxy)phenol Chemical compound OC1=CC=C(OC(F)(F)F)C=C1 WDRJNKMAZMEYOF-UHFFFAOYSA-N 0.000 description 1
- IMBBXSASDSZJSX-UHFFFAOYSA-N 4-Carboxypyrazole Chemical compound OC(=O)C=1C=NNC=1 IMBBXSASDSZJSX-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- QDNOBTKJPANVQD-UHFFFAOYSA-N 4-amino-2-chloro-5-nitrobenzonitrile Chemical compound NC1=CC(Cl)=C(C#N)C=C1[N+]([O-])=O QDNOBTKJPANVQD-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- FBUUMRBJJQXVRE-UHFFFAOYSA-N 4-bromo-1,3-benzothiazol-5-amine Chemical group NC1=CC=C2SC=NC2=C1Br FBUUMRBJJQXVRE-UHFFFAOYSA-N 0.000 description 1
- IDGCFJLWZBBNNC-UHFFFAOYSA-N 4-chloro-1,3-dihydrobenzimidazol-2-one Chemical compound ClC1=CC=CC2=C1NC(=O)N2 IDGCFJLWZBBNNC-UHFFFAOYSA-N 0.000 description 1
- ZKMUKBBWORLNLA-UHFFFAOYSA-N 4-chloro-2-fluorophenol Chemical compound OC1=CC=C(Cl)C=C1F ZKMUKBBWORLNLA-UHFFFAOYSA-N 0.000 description 1
- QDSCDFKGUAONPC-UHFFFAOYSA-N 4-chloro-2-methyl-6-nitroaniline Chemical compound CC1=CC(Cl)=CC([N+]([O-])=O)=C1N QDSCDFKGUAONPC-UHFFFAOYSA-N 0.000 description 1
- HLEWKRQSGSZHGO-UHFFFAOYSA-N 4-chloro-2-nitro-5-(trifluoromethyl)aniline Chemical compound NC1=CC(C(F)(F)F)=C(Cl)C=C1[N+]([O-])=O HLEWKRQSGSZHGO-UHFFFAOYSA-N 0.000 description 1
- WXIANZGDZCYRDS-UHFFFAOYSA-N 4-chloro-2-nitro-5-phenylmethoxyaniline Chemical compound C1=C([N+]([O-])=O)C(N)=CC(OCC=2C=CC=CC=2)=C1Cl WXIANZGDZCYRDS-UHFFFAOYSA-N 0.000 description 1
- AUFZQTVQDNPYAK-UHFFFAOYSA-N 4-chloro-2-nitro-5-piperidin-1-ylaniline Chemical compound C1=C([N+]([O-])=O)C(N)=CC(N2CCCCC2)=C1Cl AUFZQTVQDNPYAK-UHFFFAOYSA-N 0.000 description 1
- MXBKAQPVALCBEP-UHFFFAOYSA-N 4-chloro-2-nitro-5-propylsulfanylaniline Chemical compound CCCSC1=CC(N)=C([N+]([O-])=O)C=C1Cl MXBKAQPVALCBEP-UHFFFAOYSA-N 0.000 description 1
- SOMIWUJTMQGXJC-UHFFFAOYSA-N 4-chloro-2-nitro-6-(trifluoromethyl)aniline Chemical compound NC1=C([N+]([O-])=O)C=C(Cl)C=C1C(F)(F)F SOMIWUJTMQGXJC-UHFFFAOYSA-N 0.000 description 1
- YSQAWXIJOLCDIC-UHFFFAOYSA-N 4-chloro-5-(trifluoromethoxy)benzene-1,2-diamine Chemical compound NC1=CC(Cl)=C(OC(F)(F)F)C=C1N YSQAWXIJOLCDIC-UHFFFAOYSA-N 0.000 description 1
- XTNBGUVHRYTLLE-UHFFFAOYSA-N 4-chloro-5-ethylsulfanyl-2-nitroaniline Chemical compound CCSC1=CC(N)=C([N+]([O-])=O)C=C1Cl XTNBGUVHRYTLLE-UHFFFAOYSA-N 0.000 description 1
- MIGKKDPFXLVZTK-UHFFFAOYSA-N 4-chloro-5-morpholin-4-yl-2-nitroaniline Chemical compound C1=C([N+]([O-])=O)C(N)=CC(N2CCOCC2)=C1Cl MIGKKDPFXLVZTK-UHFFFAOYSA-N 0.000 description 1
- LOQLMWFVXRZASN-UHFFFAOYSA-N 4-chloro-5-nitrobenzene-1,2-diamine Chemical compound NC1=CC(Cl)=C([N+]([O-])=O)C=C1N LOQLMWFVXRZASN-UHFFFAOYSA-N 0.000 description 1
- VZXOZSQDJJNBRC-UHFFFAOYSA-N 4-chlorobenzenethiol Chemical compound SC1=CC=C(Cl)C=C1 VZXOZSQDJJNBRC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- UBNPDBHPCXITCX-UHFFFAOYSA-N 4-fluoro-2-nitro-5-propylsulfanylaniline Chemical compound CCCSC1=CC(N)=C([N+]([O-])=O)C=C1F UBNPDBHPCXITCX-UHFFFAOYSA-N 0.000 description 1
- KWEWNOOZQVJONF-UHFFFAOYSA-N 4-fluorobenzene-1,2-diamine Chemical compound NC1=CC=C(F)C=C1N KWEWNOOZQVJONF-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- NDZFWKZHVAUUTN-UHFFFAOYSA-N 4-methylsulfonyl-2-nitroaniline Chemical compound CS(=O)(=O)C1=CC=C(N)C([N+]([O-])=O)=C1 NDZFWKZHVAUUTN-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 102100033051 40S ribosomal protein S19 Human genes 0.000 description 1
- FJOIUDDFLGHEJL-UHFFFAOYSA-N 5-(3,4-dichlorophenoxy)-2-nitro-4-(trifluoromethyl)aniline Chemical compound C1=C([N+]([O-])=O)C(N)=CC(OC=2C=C(Cl)C(Cl)=CC=2)=C1C(F)(F)F FJOIUDDFLGHEJL-UHFFFAOYSA-N 0.000 description 1
- VVDIMAMYKUTSCL-UHFFFAOYSA-N 5-amino-2-chlorobenzonitrile Chemical compound NC1=CC=C(Cl)C(C#N)=C1 VVDIMAMYKUTSCL-UHFFFAOYSA-N 0.000 description 1
- PTQHTXBNGYMWER-UHFFFAOYSA-N 5-bromo-3-fluoro-2-nitroaniline Chemical compound NC1=CC(Br)=CC(F)=C1[N+]([O-])=O PTQHTXBNGYMWER-UHFFFAOYSA-N 0.000 description 1
- UOFSLKHZOPVGHG-UHFFFAOYSA-N 5-bromo-3-methylbenzene-1,2-diamine Chemical compound CC1=CC(Br)=CC(N)=C1N UOFSLKHZOPVGHG-UHFFFAOYSA-N 0.000 description 1
- RZKSZNBVDFEIFZ-UHFFFAOYSA-N 5-chloro-1-(2-methoxyethoxymethyl)-6-propan-2-ylsulfonyl-2-pyrazol-1-ylbenzimidazole Chemical compound ClC1=CC2=C(N(C(=N2)N2N=CC=C2)COCCOC)C=C1S(=O)(=O)C(C)C RZKSZNBVDFEIFZ-UHFFFAOYSA-N 0.000 description 1
- QFFUPUXKCIPJQF-UHFFFAOYSA-N 5-chloro-1-(2-methoxyethoxymethyl)-6-pyrrolidin-1-ylbenzimidazole Chemical compound C1=C2N(COCCOC)C=NC2=CC(Cl)=C1N1CCCC1 QFFUPUXKCIPJQF-UHFFFAOYSA-N 0.000 description 1
- BNQICXCZGRALQO-UHFFFAOYSA-N 5-chloro-6-methoxy-1-(2-methoxyethoxymethyl)benzimidazole Chemical compound ClC1=C(OC)C=C2N(COCCOC)C=NC2=C1 BNQICXCZGRALQO-UHFFFAOYSA-N 0.000 description 1
- UTRVMCDXCUQEEJ-UHFFFAOYSA-N 5-fluoro-2-nitro-4-(trifluoromethyl)aniline Chemical compound NC1=CC(F)=C(C(F)(F)F)C=C1[N+]([O-])=O UTRVMCDXCUQEEJ-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- ARGHSTCKHHRQHN-UHFFFAOYSA-N 6-bromo-2-chloro-4,5-dimethyl-1h-benzimidazole Chemical compound CC1=C(Br)C=C2N=C(Cl)NC2=C1C ARGHSTCKHHRQHN-UHFFFAOYSA-N 0.000 description 1
- QIAASKAALAUUCM-UHFFFAOYSA-N 6-chloro-5-(trifluoromethoxy)-1h-benzimidazole Chemical compound C1=C(Cl)C(OC(F)(F)F)=CC2=C1NC=N2 QIAASKAALAUUCM-UHFFFAOYSA-N 0.000 description 1
- NIYSTBRLTVTQTO-UHFFFAOYSA-N 6-chloro-N,N-dimethyl-2-pyrazol-1-yl-5-(trifluoromethoxy)benzimidazole-1-sulfonamide Chemical compound ClC=1C(=CC2=C(N(C(=N2)N2N=CC=C2)S(N(C)C)(=O)=O)C=1)OC(F)(F)F NIYSTBRLTVTQTO-UHFFFAOYSA-N 0.000 description 1
- LVSAGTUQWLPUCW-UHFFFAOYSA-N 6-piperidin-1-yl-5-(trifluoromethoxy)-1h-benzimidazole Chemical compound FC(F)(F)OC1=CC=2NC=NC=2C=C1N1CCCCC1 LVSAGTUQWLPUCW-UHFFFAOYSA-N 0.000 description 1
- KHODOHYLNGOJEK-UHFFFAOYSA-N 7-[(4-chlorophenyl)-[(5-methyl-1,2-oxazol-3-yl)amino]methyl]quinolin-8-ol Chemical compound O1C(C)=CC(NC(C=2C=CC(Cl)=CC=2)C=2C(=C3N=CC=CC3=CC=2)O)=N1 KHODOHYLNGOJEK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- PGFJQEMHMRGSJA-UHFFFAOYSA-N 8-bromo-2-methyl-6-nitroquinolin-5-amine Chemical compound NC1=C([N+]([O-])=O)C=C(Br)C2=NC(C)=CC=C21 PGFJQEMHMRGSJA-UHFFFAOYSA-N 0.000 description 1
- UTDVXMWARCWFFW-UHFFFAOYSA-N 8-bromo-7-[(2-fluorophenyl)methyl]-3-methylpurine-2,6-dione Chemical compound C1=2C(=O)NC(=O)N(C)C=2N=C(Br)N1CC1=CC=CC=C1F UTDVXMWARCWFFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 101710120269 Acyl-CoA thioester hydrolase YbgC Proteins 0.000 description 1
- 102400001318 Adrenomedullin Human genes 0.000 description 1
- 101800004616 Adrenomedullin Proteins 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 102100037320 Apolipoprotein A-IV Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100030907 Aryl hydrocarbon receptor nuclear translocator Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
- HIFQDPXEJLEIQE-UHFFFAOYSA-N C(C)=O.NC1=CC2=C(N(C(=N2)N2N=CC(=C2)C(=O)O)COCCOC)C=C1Cl Chemical compound C(C)=O.NC1=CC2=C(N(C(=N2)N2N=CC(=C2)C(=O)O)COCCOC)C=C1Cl HIFQDPXEJLEIQE-UHFFFAOYSA-N 0.000 description 1
- GETROXFXSFTXOI-UHFFFAOYSA-N C[ClH]S([ClH]C)(=O)=O Chemical compound C[ClH]S([ClH]C)(=O)=O GETROXFXSFTXOI-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010066477 Carnitine O-acetyltransferase Proteins 0.000 description 1
- 102100036357 Carnitine O-acetyltransferase Human genes 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- UOWXNHWJFZXEFO-UHFFFAOYSA-N ClC1=CC=CC=2N(C(N(C=21)Cl)=O)Cl Chemical compound ClC1=CC=CC=2N(C(N(C=21)Cl)=O)Cl UOWXNHWJFZXEFO-UHFFFAOYSA-N 0.000 description 1
- 101710130550 Class E basic helix-loop-helix protein 40 Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 1
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 101000793115 Homo sapiens Aryl hydrocarbon receptor nuclear translocator Proteins 0.000 description 1
- 101000881648 Homo sapiens Egl nine homolog 1 Proteins 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 101000684503 Homo sapiens Sentrin-specific protease 3 Proteins 0.000 description 1
- 101000614354 Homo sapiens Transmembrane prolyl 4-hydroxylase Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010050502 Neuropathic ulcer Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101150100944 Nos2 gene Proteins 0.000 description 1
- ASADTUOYWVHPGU-UHFFFAOYSA-N OC1=C(C(=O)OCC)C=NN1C1=NC2=CC=CC=C2N1 Chemical compound OC1=C(C(=O)OCC)C=NN1C1=NC2=CC=CC=C2N1 ASADTUOYWVHPGU-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 102100037483 POU domain, class 6, transcription factor 1 Human genes 0.000 description 1
- 101710196406 POU domain, class 6, transcription factor 1 Proteins 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000009527 Refractory anemia Diseases 0.000 description 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 1
- 102100023645 Sentrin-specific protease 3 Human genes 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 102100040472 Transmembrane prolyl 4-hydroxylase Human genes 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108010018628 Ulp1 protease Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- WOAORAPRPVIATR-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(F)(F)F)=C1 WOAORAPRPVIATR-UHFFFAOYSA-N 0.000 description 1
- XHGOCNFADOJUMW-UHFFFAOYSA-N [3-[(2-chlorophenyl)methoxy]phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(OCC=2C(=CC=CC=2)Cl)=C1 XHGOCNFADOJUMW-UHFFFAOYSA-N 0.000 description 1
- TYILTVKJHDWCKU-UHFFFAOYSA-N [3-[(4-chlorophenyl)methoxy]phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(OCC=2C=CC(Cl)=CC=2)=C1 TYILTVKJHDWCKU-UHFFFAOYSA-N 0.000 description 1
- VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 108010073614 apolipoprotein A-IV Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 150000001500 aryl chlorides Chemical class 0.000 description 1
- 150000008378 aryl ethers Chemical class 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 125000005362 aryl sulfone group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005361 aryl sulfoxide group Chemical group 0.000 description 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- HYNPZTKLUNHGPM-KKERQHFVSA-N becaplermin Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](Cc8c[nH]c9c8cccc9)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)N HYNPZTKLUNHGPM-KKERQHFVSA-N 0.000 description 1
- 229960004787 becaplermin Drugs 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- HTMQZWFSTJVJEQ-UHFFFAOYSA-N benzylsulfinylmethylbenzene Chemical class C=1C=CC=CC=1CS(=O)CC1=CC=CC=C1 HTMQZWFSTJVJEQ-UHFFFAOYSA-N 0.000 description 1
- AWHNUHMUCGRKRA-UHFFFAOYSA-N benzylsulfonylmethylbenzene Chemical class C=1C=CC=CC=1CS(=O)(=O)CC1=CC=CC=C1 AWHNUHMUCGRKRA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- UUWSLBWDFJMSFP-UHFFFAOYSA-N bromomethylcyclohexane Chemical compound BrCC1CCCCC1 UUWSLBWDFJMSFP-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- MMCOUVMKNAHQOY-UHFFFAOYSA-N carbonoperoxoic acid Chemical class OOC(O)=O MMCOUVMKNAHQOY-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 102000014509 cathelicidin Human genes 0.000 description 1
- 108060001132 cathelicidin Proteins 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000006790 cellular biosynthetic process Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- PSHRANCNVXNITH-UHFFFAOYSA-N dimethylamino acetate Chemical compound CN(C)OC(C)=O PSHRANCNVXNITH-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- JZBWUTVDIDNCMW-UHFFFAOYSA-L dipotassium;oxido sulfate Chemical compound [K+].[K+].[O-]OS([O-])(=O)=O JZBWUTVDIDNCMW-UHFFFAOYSA-L 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-M ethanethiolate Chemical compound CC[S-] DNJIEGIFACGWOD-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- NRHQARBCZRKLOV-UHFFFAOYSA-N ethyl 1-(1h-benzimidazol-2-yl)pyrazole-4-carboxylate;hydrochloride Chemical compound Cl.C1=C(C(=O)OCC)C=NN1C1=NC2=CC=CC=C2N1 NRHQARBCZRKLOV-UHFFFAOYSA-N 0.000 description 1
- OOQZTEVOKINEDE-UHFFFAOYSA-N ethyl 1-[1-(2-methoxyethoxymethyl)-6-methylsulfinyl-5-(trifluoromethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(C(F)(F)F)=C(S(C)=O)C=C2N1COCCOC OOQZTEVOKINEDE-UHFFFAOYSA-N 0.000 description 1
- HWAGSQWFTYIUDC-UHFFFAOYSA-N ethyl 1-[1-(2-trimethylsilylethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC=CC=C2N1COCC[Si](C)(C)C HWAGSQWFTYIUDC-UHFFFAOYSA-N 0.000 description 1
- NDWVTVSZRZYVJX-UHFFFAOYSA-N ethyl 1-[1-(2-trimethylsilylethoxymethyl)benzimidazol-2-yl]pyrrole-3-carboxylate Chemical compound C1=C(C(=O)OCC)C=CN1C1=NC2=CC=CC=C2N1COCC[Si](C)(C)C NDWVTVSZRZYVJX-UHFFFAOYSA-N 0.000 description 1
- YWXJSQOFQVXKJW-UHFFFAOYSA-N ethyl 1-[5-(benzylamino)-6-chloro-1-(2-methoxyethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(NCC=3C=CC=CC=3)=C(Cl)C=C2N1COCCOC YWXJSQOFQVXKJW-UHFFFAOYSA-N 0.000 description 1
- NEOSIZIKYFDKDH-UHFFFAOYSA-N ethyl 1-[5-(benzylideneamino)-6-chloro-1-(2-methoxyethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(N=CC=3C=CC=CC=3)=C(Cl)C=C2N1COCCOC NEOSIZIKYFDKDH-UHFFFAOYSA-N 0.000 description 1
- YOYPZVKGLDYOLB-UHFFFAOYSA-N ethyl 1-[5-[(2-bromoacetyl)amino]-6-chloro-1-(2-methoxyethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(NC(=O)CBr)=C(Cl)C=C2N1COCCOC YOYPZVKGLDYOLB-UHFFFAOYSA-N 0.000 description 1
- NBNSEJFILGFXRW-UHFFFAOYSA-N ethyl 1-[5-[3-[(3-chlorophenyl)methoxy]phenyl]-1-(2-trimethylsilylethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(C=3C=C(OCC=4C=C(Cl)C=CC=4)C=CC=3)=CC=C2N1COCC[Si](C)(C)C NBNSEJFILGFXRW-UHFFFAOYSA-N 0.000 description 1
- JTWCNADIKQLMFV-UHFFFAOYSA-N ethyl 1-[5-acetamido-6-chloro-1-(2-methoxyethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(NC(C)=O)=C(Cl)C=C2N1COCCOC JTWCNADIKQLMFV-UHFFFAOYSA-N 0.000 description 1
- KNPOGQGEXFSKKJ-UHFFFAOYSA-N ethyl 1-[5-anilino-6-chloro-1-(2-methoxyethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(NC=3C=CC=CC=3)=C(Cl)C=C2N1COCCOC KNPOGQGEXFSKKJ-UHFFFAOYSA-N 0.000 description 1
- RIBLRBWYPCJPPX-UHFFFAOYSA-N ethyl 1-[5-bromo-1-(2-trimethylsilylethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(Br)=CC=C2N1COCC[Si](C)(C)C RIBLRBWYPCJPPX-UHFFFAOYSA-N 0.000 description 1
- RPBJEMSAMSLFPJ-UHFFFAOYSA-N ethyl 1-[5-chloro-1-(2-methoxyethoxymethyl)-6-propan-2-ylsulfonylbenzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(Cl)=C(S(=O)(=O)C(C)C)C=C2N1COCCOC RPBJEMSAMSLFPJ-UHFFFAOYSA-N 0.000 description 1
- TWLIYDGTGMSXKY-UHFFFAOYSA-N ethyl 1-[5-chloro-6-(phenylsulfamoyl)-1h-benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(S(=O)(=O)NC=3C=CC=CC=3)=C(Cl)C=C2N1 TWLIYDGTGMSXKY-UHFFFAOYSA-N 0.000 description 1
- HWCJZGAATHSTQQ-UHFFFAOYSA-N ethyl 1-[6-[3-[(3-chlorophenyl)methoxy]phenyl]-1-(2-trimethylsilylethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC=C(C=3C=C(OCC=4C=C(Cl)C=CC=4)C=CC=3)C=C2N1COCC[Si](C)(C)C HWCJZGAATHSTQQ-UHFFFAOYSA-N 0.000 description 1
- XILZXTWZHXXYEX-UHFFFAOYSA-N ethyl 1-[6-bromo-1-(2-trimethylsilylethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC=C(Br)C=C2N1COCC[Si](C)(C)C XILZXTWZHXXYEX-UHFFFAOYSA-N 0.000 description 1
- TULDHQXEPPUOMS-UHFFFAOYSA-N ethyl 1-[6-chloro-1-(2-methoxyethoxymethyl)-5-(2-morpholin-4-ylethylamino)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(NCCN3CCOCC3)=C(Cl)C=C2N1COCCOC TULDHQXEPPUOMS-UHFFFAOYSA-N 0.000 description 1
- MVMQVOZYSOQLHJ-UHFFFAOYSA-N ethyl 1-[6-chloro-1-(2-methoxyethoxymethyl)-5-(3-methylphenyl)sulfonylbenzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(S(=O)(=O)C=3C=C(C)C=CC=3)=C(Cl)C=C2N1COCCOC MVMQVOZYSOQLHJ-UHFFFAOYSA-N 0.000 description 1
- PTIPUBIWDMQPIV-UHFFFAOYSA-N ethyl 1-[6-chloro-1-(2-methoxyethoxymethyl)-5-(phenylsulfamoyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(S(=O)(=O)NC=3C=CC=CC=3)=C(Cl)C=C2N1COCCOC PTIPUBIWDMQPIV-UHFFFAOYSA-N 0.000 description 1
- JLSJQXYPGFMJTL-UHFFFAOYSA-N ethyl 1-[6-chloro-1-(2-methoxyethoxymethyl)-5-[(2,4,6-trimethylphenyl)methylsulfanyl]benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(SCC=3C(=CC(C)=CC=3C)C)=C(Cl)C=C2N1COCCOC JLSJQXYPGFMJTL-UHFFFAOYSA-N 0.000 description 1
- BOWPBJWHKHRBDI-UHFFFAOYSA-N ethyl 1-[6-chloro-1-(2-methoxyethoxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(NC(=O)CN3CCOCC3)=C(Cl)C=C2N1COCCOC BOWPBJWHKHRBDI-UHFFFAOYSA-N 0.000 description 1
- MDKTUBLLGVAFAY-UHFFFAOYSA-N ethyl 1-[6-chloro-1-(2-methoxyethoxymethyl)-5-[(2-nitrophenyl)disulfanyl]benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(SSC=3C(=CC=CC=3)[N+]([O-])=O)=C(Cl)C=C2N1COCCOC MDKTUBLLGVAFAY-UHFFFAOYSA-N 0.000 description 1
- SGZQPPXSYOQPDD-UHFFFAOYSA-N ethyl 1-[6-chloro-1-(2-methoxyethoxymethyl)-5-[4-(trifluoromethoxy)phenyl]sulfanylbenzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(SC=3C=CC(OC(F)(F)F)=CC=3)=C(Cl)C=C2N1COCCOC SGZQPPXSYOQPDD-UHFFFAOYSA-N 0.000 description 1
- PDGZIBVQSBKXBB-UHFFFAOYSA-N ethyl 1-[6-chloro-1-(2-methoxyethoxymethyl)-5-nitrobenzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC([N+]([O-])=O)=C(Cl)C=C2N1COCCOC PDGZIBVQSBKXBB-UHFFFAOYSA-N 0.000 description 1
- RHQKLTNTTGYCPB-UHFFFAOYSA-N ethyl 1-[6-chloro-5-(4-chlorophenyl)sulfanyl-1-(2-methoxyethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(SC=3C=CC(Cl)=CC=3)=C(Cl)C=C2N1COCCOC RHQKLTNTTGYCPB-UHFFFAOYSA-N 0.000 description 1
- NENBFKYFDMXZLP-UHFFFAOYSA-N ethyl 1-[6-chloro-5-(4-chlorophenyl)sulfonyl-1-(2-methoxyethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(S(=O)(=O)C=3C=CC(Cl)=CC=3)=C(Cl)C=C2N1COCCOC NENBFKYFDMXZLP-UHFFFAOYSA-N 0.000 description 1
- SMQJHWOIPIBTLK-UHFFFAOYSA-N ethyl 1-[6-chloro-5-(cyclopropylsulfonylamino)-1-(2-methoxyethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(NS(=O)(=O)C3CC3)=C(Cl)C=C2N1COCCOC SMQJHWOIPIBTLK-UHFFFAOYSA-N 0.000 description 1
- MKPKXWXRQMWJRS-UHFFFAOYSA-N ethyl 1-[6-chloro-5-chlorosulfonyl-1-(2-methoxyethoxymethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(S(Cl)(=O)=O)=C(Cl)C=C2N1COCCOC MKPKXWXRQMWJRS-UHFFFAOYSA-N 0.000 description 1
- CZKZMDISDNZWRJ-UHFFFAOYSA-N ethyl 1-[6-ethylsulfinyl-1-(2-methoxyethoxymethyl)-5-(trifluoromethyl)benzimidazol-2-yl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=NC2=CC(C(F)(F)F)=C(S(=O)CC)C=C2N1COCCOC CZKZMDISDNZWRJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 108010093115 growth factor-activatable Na-H exchanger NHE-1 Proteins 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000053692 human EGLN1 Human genes 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
- MKQLBNJQQZRQJU-UHFFFAOYSA-N morpholin-4-amine Chemical compound NN1CCOCC1 MKQLBNJQQZRQJU-UHFFFAOYSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- BSUFVRGLMWXUDX-UHFFFAOYSA-N n,n-dichloro-2-nitroaniline Chemical compound [O-][N+](=O)C1=CC=CC=C1N(Cl)Cl BSUFVRGLMWXUDX-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- CXHCHCMYVUBLIC-UHFFFAOYSA-N n-[1-(4-chlorophenyl)-2,4,6-trioxo-5-(trifluoromethyl)-7h-pyrrolo[2,3-d]pyrimidin-5-yl]furan-2-carboxamide Chemical compound O=C1NC(N(C(=O)NC2=O)C=3C=CC(Cl)=CC=3)=C2C1(C(F)(F)F)NC(=O)C1=CC=CO1 CXHCHCMYVUBLIC-UHFFFAOYSA-N 0.000 description 1
- ILCQYORZHHFLNL-UHFFFAOYSA-N n-bromoaniline Chemical compound BrNC1=CC=CC=C1 ILCQYORZHHFLNL-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NTNWKDHZTDQSST-UHFFFAOYSA-N naphthalene-1,2-diamine Chemical compound C1=CC=CC2=C(N)C(N)=CC=C21 NTNWKDHZTDQSST-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- XTBLDMQMUSHDEN-UHFFFAOYSA-N naphthalene-2,3-diamine Chemical compound C1=CC=C2C=C(N)C(N)=CC2=C1 XTBLDMQMUSHDEN-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N ortho-methoxybenzoic acid Natural products COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 108010031256 phosducin Proteins 0.000 description 1
- 125000005541 phosphonamide group Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 230000026341 positive regulation of angiogenesis Effects 0.000 description 1
- 230000019260 positive regulation of glycolysis Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- IKNCGYCHMGNBCP-UHFFFAOYSA-N propan-1-olate Chemical compound CCC[O-] IKNCGYCHMGNBCP-UHFFFAOYSA-N 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 150000005229 pyrazolopyridines Chemical class 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000006476 reductive cyclization reaction Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 229940116157 regranex Drugs 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000028981 regulation of cellular metabolic process Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- WMXCDAVJEZZYLT-UHFFFAOYSA-N tert-butylthiol Chemical compound CC(C)(C)S WMXCDAVJEZZYLT-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006337 tetrafluoro ethyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Description
nは、2〜4であり、
R1は、独立して、H、ハロ、−C1〜4アルキル、−C3〜8シクロアルキル−C1〜4ペルハロアルキル、トリフルオロC1〜4アルコキシ、−OH、−NO2、−CN、CO2H、−OC1〜4アルキル、−SC1〜4アルキル、−S(C1〜4アルキル)−Rc、−S(O)2(C1〜4アルキル)−Rc、−S(O)−C1〜4アルキル、−SO2−C1〜4アルキル、−S−Rc、−S(O)−Rc、−SO2−Rc、−SO2−NH−Rd、−O−Rc、−CH2−O−Rc、−C(O)NH−Rc、−NRaRb、所望によりRdで置換されたベンジルオキシ、所望により1つ以上のRdで置換されたフェニル又は単環式ヘテロアリール、所望によりO、S又はNを含む−C3〜8シクロアルキルから選択され、ここで、−C3〜8シクロアルキルは所望によりRdで置換される、及び2つの隣接するR1基は結合して、所望により置換されている所望により1つ以上のO、S又はNを含む3〜8員環を形成することができる、
Ra及びRbは、それぞれ独立して、H、C1〜4アルキル、−C(O)C1〜4アルキル、−C(O)−Rc、−C(O)CH2−Re、C1〜4アルキル−Re、−SO2−Rc、−SO2−C1〜4アルキル、所望によりRdで置換されたフェニル、所望によりRdで置換されたベンジル又は所望によりRdで置換されている単環式ヘテロアリール環であり、あるいはRa及びRbは、それらが付着した窒素と一緒に取られて、所望により1つ以上のO、S又はNを含有する、所望により置換された単環式ヘテロシクロアルキル環を形成し、
Rcは、−C3〜8シクロアルキル、所望によりRdで置換されたフェニル、所望によりRdで置換されたフェニル、又は所望によりRdで置換された単環式ヘテロアリール環であり、
Rdは、独立して、−H、ハロ、−OH、−C1〜4アルキル又は−C1〜4ペルハロアルキル、トリフルオロC1〜4アルコキシ、−OC1〜4アルキル、−O−フェニル、又は−O−ベンジルであり、
Reは、所望により1つ以上のO、S又はNを含有する−C3〜8ヘテロシクロアルキルであり、
R2及びR3は両方とも、H、−CF3、又は−CH3であり、
各Zは、C又はNであり、ただし2つを超えるZが同時にNであることはなく、
これらのエナンチオマー、ジアステレオマー、ラセミ体、又は製薬上許容される塩を含む。
以下の実施例に記述する化合物及び対応する分析データを得る際、特に明記しない限り、以下の実験及び分析プロトコルに従った。
実施例1と同様の方法で、工程Aにおいて2,5,6−トリクロロ−1H−ベンゾイミダゾールを2−クロロベンゾイミダゾールの代わりに用い、標題化合物を調製した。MS(ESI/CI):C11H6Cl2N4O2の質量計算値、297.1;m/z実測値、296.0[M−H]-。1H NMR(500MHz、DMSO−d6):14.18−12.52(br s,2H),8.89(d,J 0.5Hz,1H),8.31(d,J=0.5Hz,1H),7.80(s,2H)。
工程A:5,6−ジクロロ−1,3−ジヒドロ−ベンゾイミダゾル−2−オン:乾燥DMF(200mL)中の4,5−ジクロロ−ベンゼン−1,2−ジアミン(25g、0.14mol)溶液に、CDI(23g、0.14mol)を固体として加えた。この反応溶液を室温で1時間攪拌し、次に水(500mL)を加えた。沈殿固形物を濾過により回収し、水で洗浄し、完全に乾燥させて、標題化合物を得た(26.0g、90%)。この粗生成物を、更に精製することなく、次の反応に使用した。
工程A:5−ベンジルスルファニル−4−クロロ−2−ニトロ−フェニルアミン。4,5−ジクロロ−2−ニトロ−フェニルアミン(3.00g、14.5mmol)及びDMF(72mL)の混合物に、K2CO3(5.31g、29.0mmol)及びフェニル−メタンチオール(3.94g、31.7mmol)を加えた。この反応混合物を70℃に18時間加熱してから、23℃まで冷ました。この反応混合物をEtOAc(200mL)に溶かし、飽和重炭酸ナトリウム溶液(100mL)で洗い、食塩水(3×100mL)で洗った。有機層を合わせ、乾燥させ、濾過し、減圧下で濃縮した。残留物を精製し(FCC)(5〜45%のEtOAc/ヘキサン)、標題化合物を得た(2.39g、56%)。MS(ESI/CI):C13H11ClN2O2Sの質量計算値、294.0;m/z実測値、295.0[M+H]+。1H NMR(600MHz、DMSO−d6):7.96(s,1H),7.56(s,2H),7.50(d,J=7.2Hz,2H),7.37(t,J=7.5Hz,2H),7.31(t,J=7.4Hz,1H),7.05(s,1H),4.27(s,2H)。
工程A:1−[5−tert−ブチルスルファニル−6−クロロ−1−(2−メトキシ−エトキシメチル)−1H−ベンゾイミダゾル−2−イル]−1H−ピラゾール−4−カルボン酸エチルエステル。実施例66、方法A、工程A〜Bと同様の方法で、工程Aにおいて2−メチル−プロパン−2−チオールをフェニル−メタンチオールの代わりに用い、標題化合物を調製し、位置異性体の1:1混合物を得た。MS(ESI/CI):C21H27ClN4O4Sの質量計算値、466.1;m/z実測値、467.1[M+H]+。1H NMR(400MHz、CDCl3):8.89−8.88(m,2H),8.19(s,2H),8.03(s,1H),7.93(s,1H),7.85(s,1H),7.78(s,1H),6.17(s,2H),6.13(s,2H),4.39−4.33(m,4H),3.71−3.64(m,4H),3.50−3.42(m,4H),3.31(s,J=5.1Hz,3H),3.30(s,3H),1.43−1.29(m,24H)。
、474.1;m/z実測値、475.1[M+H]+。1H NMR(400MHz、CDCl3):8.94(d,J=0.6Hz,1H),8.58(s,1H),8.22(s,1H),8.08(s,1H),6.34−6.23(m,2H),4.38(q,J=7.1Hz,2H),3.74−3.66(m,2H),3.51−3.41(m,2H),3.28(s,3H),2.81(s,3H),1.40(t,J=7.1Hz,3H)。
実施例27と同様の方法で、工程Aにおいて5−クロロ−2−ニトロ−4−トリフルオロメトキシ−フェニルアミンを3−クロロ−2−ニトロ−フェニルアミンの代わりに用い、標題化合物を調製した。MS(ESI/CI):C12H6ClF3N4O3の質量計算値、346.0;m/z実測値、347.0[M+H]+。1H NMR(500MHz、DMSO−d6):13.37(s,1H),8.88(s,1H),8.29(s,1H),7.80(s,1H),7.71(s,1H)。
工程A:6−クロロ−5−トリフルオロメトキシ−1H−ベンゾイミダゾール。5−クロロ−2−ニトロ−4−トリフルオロメトキシ−フェニルアミン(2.00g、7.80mmol)、亜ジチオン酸ナトリウム(7.06g、40.5mmol)、オルト蟻酸トリメチル(23.1mL、210mmol)、DMF(23mL)、及び酢酸(4.0mL)の混合物を、密封試験管中、100℃で15時間加熱した。この反応混合物を23℃に冷まし、EtOAc(100mL)と飽和NaHCO3水溶液(100mL)とに分割した。有機層を回収し、水性層をEtOAcで抽出した(2×80mL)。合わせた有機層を乾燥させ、濾過し、減圧下で濃縮した。残留物を精製し(FCC)(0〜15%のMeOH/DCM)、標題化合物を得た(1.46g、78%)。MS(ESI/CI):C8H4ClF3N2Oの質量計算値、236.0;m/z実測値、237.0[M+H]+。1H NMR(500MHz、CDCl3):8.11(s,1H),7.74(s,1H),7.64(s,1H)。
工程A:4−クロロ−5−トリフルオロメトキシ−ベンゼン−1,2−ジアミン。5−クロロ−2−ニトロ−4−トリフルオロメトキシ−フェニルアミン(180g、0.7mol、1.0当量)を乾燥DMF(1L)中に溶かし、5%Pt/C含有の50.2%水(4.0g)を加えた。この反応溶液を室温で16時間、水素添加した(344.7kPa(50psi))。HPLC分析で、反応完了が示された。MS[M+H]+は225.2であった。この反応溶液を、分離することなく次の工程で使用した。
0[M+H]+。
本明細書に示されているように(前記表を参照)、例示された化合物の生物学的活性が、次のプロトコルに従って測定された。
の発現及び精製GenBankアクセッションID NM_022051のアミノ酸181〜417を含むヒトPHD2発現コンストラクトが、N−末端ヒスチジンタグ及びSmt3タグの両方を組み込んでpBADベクター(Invitrogen)にクローン化され、これらのタグは両方ともUlp1によって切断される。タンパク質産生は、100mg/mLアンピシリンを含むTerrific Broth中で成長したBL21細胞での発現によって達成された。細胞培養は、37℃で接種され、OD600が0.8まで成長させた。培養は、0.1%アラビノースで誘導され、225rpmで継続的に振盪しながら20℃で一晩成長させた。細胞は次に遠心分離にかけて採取され、−80℃で保存された。細胞ペレットを緩衝液A(50mM Tris−HCl pH7.2、100mM NaCl、100mM L−アルギニン、1mM TCEP、0.05%(w/v)NP−40、50mMイミダゾール)中に懸濁させ、次にリゾチーム及びベンゾナーゼを加えた。超音波処理によって細胞を溶解させ、この溶解物を遠心分離により透明にした(15,000rpm、90分間、4℃)。HisTrap Crude FFカラム(GE Healthcare)を用いたニッケル親和性クロマトグラフィーによって、タンパク質を精製した。50〜200mMイミダゾール勾配で、試料を緩衝液Aに溶出させた。Ulp1プロテアーゼによるSmtタグの切断は、緩衝液Aに対する透析を行い一晩インキュベートすることにより達成された。PHD2181〜417試料を次に第二のHisTrap Crude FFカラム(GE Healthcare)に通し、切断されていないタンパク質を除去した。次にこの通過液(flow-through)を、50mM MES pH6.0、1mM TCEP、5mM NaClに透析し、HiTrap SP Cation Exchangeカラム(GE Healthcare)でのイオン交換クロマトグラフィーにかけた。PHD2181〜417タンパク質を0〜0.2M NaCl勾配で溶出させた。Superdex 75 Size Exclusion Column(GE Healthcare)でのサイズ排除クロマトグラフィーによる更なる精製のため、分画を蓄積した。最終的なタンパク質を4mg/mLに濃縮し、10mM PIPES pH7.0、100mM NaCl、0.5mM TCEPで透析した。このタンパク質は、ゲル電気泳動により、純度>95%を有することが測定された。
ポリペプチドの酵素活性評価を行う前に、試験化合物と共にPHD2181〜417ポリペプチド(3μg)を30分間プリインキュベートした。次にPHD酵素検定を実施した。これは、精製PHD2181〜417ポリペプチド(3μg)と化合物との混合物を、反応緩衝液(40mM Tris−HCl、pH7.5、0.4mg/mLカタラーゼ、0.5mM DTT、1mMアスコルベート)中に、残基[KNPFSTGDTDLDLEMLAPYIPMDDDFQLRSFDQLS](10μM、California Peptide Research Inc.、カリフォルニア州ナパ)を含む合成HIF−1αペプチド、及び[5−14C]−2−オキソグルタル酸(50mCi/mmol、Moravek Chemicals、カリフォルニア州ブレア)を含む、反応混合液0.5mLに入れ、化合物の存在下において10分間置くことによって行われた。50μLの70mM H3PO4及び50μLの500mM NaH2PO4、pH3.2を加えることにより、反応を止めた。反応混合物を、30%過塩素酸中で調製した100μLの0.16M DNPと共にインキュベートすることによって、[5−14C]−2−オキソグルタル酸から分離することにより、[14C]−コハク酸の検出が実施された。次に、50mLの未標識20mM 2−オキソグルタル酸/20mMコハク酸(放射能の担体)をこの混合物に加え、室温で30分間、反応を進行させた。この反応物を次に、50mLの1M 2−オキソグルタル酸と共に更に30分間室温でインキュベートし、過剰なDNPを沈殿させた。この反応物を次に、2800×g、室温で10分間遠心分離にかけ、上清中の[14C]−コハク酸を、沈殿した[14C]−ジニトロフェニルヒドラゾンから分離した。上清の分画(400μL)を、ベータカウンター(Beckman Coulter、カリフォルニア州フラートン)を用いて計測した。PHD2181〜417活性の阻害は、[14C]−コハク酸産生の減少として測定された。IC50値は、GraphPad Prism(バージョン4.02)(Graph Pad Software、カリフォルニア州サンディエゴ)を用いて3パラメータ論理関数にデータを適合させることにより見積もられた。最大10μMのIC50値が定量化され、それ以外は>10μMとして記載された。本検定では、すべての化合物が100% DMSO(w/v)で10mMに希釈され、10μM〜3nMの半対数連続希釈(最終濃度2% DMSO(w/v))で試験された。
Hep−3B細胞(ATCC、バージニア州マナサス)を、96ウェルプレートで、ウェル当たり細胞数20,000、100μL DMEM(ウシ胎児血清10%、非必須アミノ酸1%、ペニシリン50IU/mL、及びストレプトマイシン50μg/mLを含む)中に蒔いた(細胞培養試薬はすべてInvitrogen、カリフォルニア州カールスバッド)。蒔いてから24時間後、化合物を加え、更に24時間インキュベートした。すべての試験化合物は、100% DMSO(w/v)中に10mMで溶解され、浸潤状態で試験され、最終化合物濃度は1% DMSO(w/v)中100μMであった。次に、上清50マイクロリットルを、ヒト低酸素症検定キット(Meso−Scale Discovery、メリーランド州ゲーサーズバーグ)に移した。上清中のエリスロポエチンが、以下のようにメーカーの指示書に従って検出された。EPO検出プレートを、PBS中3% BSAで一晩ブロックし、上清50μLを、軌道振盪器中、室温で2時間インキュベートした。0.5μg/mLの抗EPO検出抗体25マイクロリットルを加え、軌道振盪器中、室温で2時間置いた。PBSで3回洗浄した後、原液の読み取り用緩衝液(read buffer)150μLを加え、プレートをMSD SECTOR装置で測定する。次に、検定の対照化合物(7−[(4−クロロ−フェニル)−(5−メチル−イソキサゾル−3−イルアミノ)−メチル]−キノリン−8−オール)と比較した、10μM又は100μMの化合物の存在におけるEPO分泌のパーセンテージを測定することにより、データを分析した。データは、対照化合物に対するEPO分泌のパーセンテージとして報告され、再現性は10%以内であった。
Claims (4)
- 式(I):
nは、2、4であり、nが4のときZはCであり、nが2のとき1つのZがCであり2つのZがNであり、
各R1が、独立して、−C1〜4アルキル、−C3〜8シクロアルキル −C1〜4アルキルスルホニル、−C1〜4アルキルスルフィニル、−C1〜4アルキルスルファニル、−NO2、−NH2、−NH−C1〜4アルキル、−NH−SO2−C3〜8シクロアルキル、−NH−SO2−C1〜4アルキル、−NH−C(O)−C1〜4アルキル、−CN、−CO2H、−OC1〜4アルキル、−NH−(CH2)2−モルホリン、−NH(CO)CH2−モルホリン、−NHC(O)−CH2−ピペリジン、−NHC(O)−CH2−(N−メチルピペラジン)、−NH−C1〜4アルキル−モルホリン、ピロリジン、ピペリジン、及びモルホリンから選択され、
R2及びR3は両方とも、Hである。]
のPHD阻害用の化合物、又はこれらのエナンチオマー、ジアステレオマー、ラセミ体、若しくは製薬上許容される塩。 - 製薬上許容される賦形剤と、有効量の式(I):
nは、2、4であり、nが4のときZはCであり、nが2のとき1つのZがCであり2つのZがNであり、
各R1が、独立して、−C1〜4アルキル、−C3〜8シクロアルキル −C1〜4アルキルスルホニル、−C1〜4アルキルスルフィニル、−C1〜4アルキルスルファニル、−NO2、−NH2、−NH−C1〜4アルキル、−NH−SO2−C3〜8シクロアルキル、−NH−SO2−C1〜4アルキル、−NH−C(O)−C1〜4アルキル、−CN、−CO2H、−OC1〜4アルキル、−NH−(CH2)2−モルホリン、−NH(CO)CH2−モルホリン、−NHC(O)−CH2−ピペリジン、−NHC(O)−CH2−(N−メチルピペラジン)、−NH−C1〜4アルキル−モルホリン、ピロリジン、ピペリジン、及びモルホリンから選択され、
R2及びR3は両方とも、Hである。]
のPHD阻害用の化合物、又はこれらのエナンチオマー、ジアステレオマー、ラセミ体、若しくは製薬上許容される塩とを含む、製薬組成物。 - 治療的有効量のPHD阻害用の式(I):
nは、2、4であり、nが4のときZはCであり、nが2のとき1つのZがCであり2つのZがNであり、
各R1が、独立して、−C1〜4アルキル、−C3〜8シクロアルキル −C1〜4アルキルスルホニル、−C1〜4アルキルスルフィニル、−C1〜4アルキルスルファニル、−NO2、−NH2、−NH−C1〜4アルキル、−NH−SO2−C3〜8シクロアルキル、−NH−SO2−C1〜4アルキル、−NH−C(O)−C1〜4アルキル、−CN、−CO2H、−OC1〜4アルキル、−NH−(CH2)2−モルホリン、−NH(CO)CH2−モルホリン、−NHC(O)−CH2−ピペリジン、−NHC(O)−CH2−(N−メチルピペラジン)、−NH−C1〜4アルキル−モルホリン、ピロリジン、ピペリジン、及びモルホリンから選択され、
R2及びR3は両方とも、Hである。]
の化合物、又はこれらのエナンチオマー、ジアステレオマー、ラセミ体、若しくは製薬上許容される塩を患者に投与することにより、貧血、低酸素症、虚血、末梢血管疾患、心筋梗塞、脳卒中、糖尿病、肥満、炎症性腸疾患、潰瘍性大腸炎、クローン病、創傷、感染症、火傷及び骨折を治療するための医薬を製造するための、式(I)の化合物、又はこれらのエナンチオマー、ジアステレオマー、ラセミ体、若しくは製薬上許容される塩の使用方法。 - 治療的有効量のPHD阻害用の式(I):
nは、2、4であり、nが4のときZはCであり、nが2のとき1つのZがCであり2つのZがNであり、
各R1が、独立して、−C1〜4アルキル、−C3〜8シクロアルキル −C1〜4アルキルスルホニル、−C1〜4アルキルスルフィニル、−C1〜4アルキルスルファニル、−NO2、−NH2、−NH−C1〜4アルキル、−NH−SO2−C3〜8シクロアルキル、−NH−SO2−C1〜4アルキル、−NH−C(O)−C1〜4アルキル、−CN、−CO2H、−OC1〜4アルキル、−NH−(CH2)2−モルホリン、−NH(CO)CH2−モルホリン、−NHC(O)−CH2−ピペリジン、−NHC(O)−CH2−(N−メチルピペラジン)、−NH−C1〜4アルキル−モルホリン、ピロリジン、ピペリジン、及びモルホリンから選択され、
R2及びR3は両方とも、Hである。]
の化合物、又はこれらのエナンチオマー、ジアステレオマー、ラセミ体、若しくは製薬上許容される塩を患者に投与することにより、低酸素症を治療するための医薬を製造するための、式(I)の化合物、又はこれらのエナンチオマー、ジアステレオマー、ラセミ体、若しくは製薬上許容される塩の使用方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4853108P | 2008-04-28 | 2008-04-28 | |
US61/048,531 | 2008-04-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011507570A Division JP6022769B2 (ja) | 2008-04-28 | 2009-04-28 | プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017229865A Division JP2018065841A (ja) | 2008-04-28 | 2017-11-30 | プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016147877A JP2016147877A (ja) | 2016-08-18 |
JP6254624B2 true JP6254624B2 (ja) | 2017-12-27 |
Family
ID=40756595
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011507570A Expired - Fee Related JP6022769B2 (ja) | 2008-04-28 | 2009-04-28 | プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール |
JP2016043107A Expired - Fee Related JP6254624B2 (ja) | 2008-04-28 | 2016-03-07 | プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール |
JP2017229865A Withdrawn JP2018065841A (ja) | 2008-04-28 | 2017-11-30 | プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール |
JP2019112687A Active JP6900424B2 (ja) | 2008-04-28 | 2019-06-18 | プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール |
JP2021100045A Withdrawn JP2021152045A (ja) | 2008-04-28 | 2021-06-16 | プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011507570A Expired - Fee Related JP6022769B2 (ja) | 2008-04-28 | 2009-04-28 | プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017229865A Withdrawn JP2018065841A (ja) | 2008-04-28 | 2017-11-30 | プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール |
JP2019112687A Active JP6900424B2 (ja) | 2008-04-28 | 2019-06-18 | プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール |
JP2021100045A Withdrawn JP2021152045A (ja) | 2008-04-28 | 2021-06-16 | プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール |
Country Status (16)
Country | Link |
---|---|
US (8) | US8759345B2 (ja) |
EP (1) | EP2294066B9 (ja) |
JP (5) | JP6022769B2 (ja) |
CN (2) | CN102076680B (ja) |
BR (1) | BRPI0911444B8 (ja) |
CA (1) | CA2722772C (ja) |
CY (1) | CY1115621T1 (ja) |
DK (1) | DK2294066T3 (ja) |
ES (1) | ES2523720T3 (ja) |
HK (1) | HK1155447A1 (ja) |
HR (1) | HRP20141038T2 (ja) |
PL (1) | PL2294066T3 (ja) |
PT (1) | PT2294066E (ja) |
RU (1) | RU2531354C2 (ja) |
SI (1) | SI2294066T1 (ja) |
WO (2) | WO2009134750A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019167383A (ja) * | 2008-04-28 | 2019-10-03 | ヤンセン ファーマシューティカ エヌ.ベー. | プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2360316B1 (es) | 2008-12-10 | 2012-05-08 | Antonio Avila Chulia | Procedimiento para la encriptación y autentificación de una señal de datos. |
US8937078B2 (en) | 2009-02-10 | 2015-01-20 | Janssen Pharmaceutica Nv | Quinazolinones as prolyl hydroxylase inhibitors |
CA2768832A1 (en) * | 2009-07-23 | 2011-01-27 | Vanderbilt University | Substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mglur4 potentiators |
US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
US8242284B1 (en) * | 2009-09-21 | 2012-08-14 | The United States Of America As Represented By The United States Department Of Energy | Anti-cancer agents based on 6-trifluoromethoxybenzimidazole derivatives and method of making |
JP2013510178A (ja) * | 2009-11-06 | 2013-03-21 | ヴァンダービルト ユニバーシティー | mGluR4アロステリック増強剤としてのアリールおよびヘテロアリールスルホン、組成物、および神経機能不全を治療する方法 |
US8680098B2 (en) * | 2010-03-05 | 2014-03-25 | Janssen Pharmaceutica, Nv | Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators |
CN103209981B (zh) * | 2010-09-10 | 2016-12-28 | 盐野义制药株式会社 | 具有ampk活化作用的杂环稠合咪唑衍生物 |
GB201102659D0 (en) | 2011-02-15 | 2011-03-30 | Isis Innovation | Assay |
CN102219745B (zh) * | 2011-04-15 | 2013-10-30 | 清华大学深圳研究生院 | 2-芳基取代苯并咪唑类衍生物及其制备方法与应用 |
GB201113101D0 (en) | 2011-07-28 | 2011-09-14 | Isis Innovation | Assay |
WO2013043624A1 (en) * | 2011-09-23 | 2013-03-28 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
WO2013043621A1 (en) | 2011-09-23 | 2013-03-28 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
EP2776023B1 (en) * | 2011-10-25 | 2016-03-09 | Janssen Pharmaceutica, N.V. | Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid |
JPWO2014030716A1 (ja) * | 2012-08-23 | 2016-08-08 | 田辺三菱製薬株式会社 | ピラゾロピリミジン化合物 |
TW201534597A (zh) | 2013-06-20 | 2015-09-16 | Ab Science | 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物 |
AU2015311333B2 (en) | 2014-09-02 | 2017-11-16 | Sunshine Lake Pharma Co., Ltd. | Quinolinone compound and use thereof |
ES2837396T3 (es) | 2016-11-23 | 2021-06-30 | Bayer Cropscience Ag | Derivados de 2-[3-(alquilsulfonil)-2H-indazol-2-il]-3H-imidazo[4,5-b]piridina y compuestos similares como pesticidas |
WO2020054788A1 (ja) * | 2018-09-13 | 2020-03-19 | キッセイ薬品工業株式会社 | イミダゾピリジノン化合物 |
TWI803696B (zh) * | 2018-09-14 | 2023-06-01 | 日商橘生藥品工業股份有限公司 | 次黃嘌呤化合物 |
CN113382729A (zh) * | 2018-10-03 | 2021-09-10 | 阿克比治疗有限公司 | 用于治疗炎症性障碍的苯并咪唑衍生物 |
CN110305072B (zh) * | 2019-06-25 | 2023-09-19 | 中国药科大学 | 具有磷酸二酯酶4d和酸性鞘磷脂酶抑制活性的化合物及其应用 |
CN115135384B (zh) | 2019-11-28 | 2024-03-22 | 日本农药株式会社 | 苯并咪唑化合物或其盐类、和含有该化合物的农艺和园艺用杀虫杀螨剂以及其使用方法 |
JP7385467B2 (ja) * | 2019-12-26 | 2023-11-22 | キッセイ薬品工業株式会社 | ヒポキサンチン化合物 |
CN113248475B (zh) * | 2020-02-11 | 2023-03-17 | 中国科学院上海药物研究所 | 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途 |
EP4092028A4 (en) * | 2020-03-11 | 2024-02-07 | Kissei Pharmaceutical Co., Ltd. | CRYSTAL OF A HYPOXANTHINE COMPOUND |
JP7504822B2 (ja) | 2020-03-12 | 2024-06-24 | キッセイ薬品工業株式会社 | イミダゾピリジノン化合物を含む医薬組成物 |
WO2021216530A1 (en) | 2020-04-20 | 2021-10-28 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
CN112209885A (zh) * | 2020-09-07 | 2021-01-12 | 宁夏大漠药业有限公司 | 芬苯达唑生产工艺及生产装置 |
WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
WO2022251563A1 (en) | 2021-05-27 | 2022-12-01 | Keryx Biopharmaceuticals, Inc. | Pediatric formulations of ferric citrate |
USD1029155S1 (en) | 2021-06-25 | 2024-05-28 | Spin Master Ltd. | Toy |
US11376515B1 (en) * | 2021-06-29 | 2022-07-05 | Spin Master Ltd. | Transformable toy |
US11712636B1 (en) | 2022-08-12 | 2023-08-01 | Spin Master Ltd. | Transformable toy |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60227260A (ja) | 1983-11-14 | 1985-11-12 | Toppan Printing Co Ltd | セツトアツプ方法 |
EP0266940B1 (en) | 1986-10-22 | 1992-12-16 | Schering Corporation | Use of recombinant human alpha interferon for the manufacture of a medicament for the treatment of aids virus |
DE3824658A1 (de) | 1988-07-15 | 1990-01-18 | Schering Ag | N-hetaryl-imidazolderivate |
US5258362A (en) | 1991-06-11 | 1993-11-02 | Abbott Laboratories | Renin inhibiting compounds |
ATE206702T1 (de) | 1995-06-06 | 2001-10-15 | Pfizer | Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren |
DE19649460A1 (de) | 1996-11-26 | 1998-05-28 | Bayer Ag | Neue substituierte Pyrazolderivate |
ATE253073T1 (de) | 1997-03-07 | 2003-11-15 | Metabasis Therapeutics Inc | Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase |
DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
EP1454902A1 (en) | 1998-02-27 | 2004-09-08 | Pfizer Products Inc. | N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia |
US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
PT1644336E (pt) | 2003-06-06 | 2011-04-21 | Fibrogen Inc | Compostos de heteroarilo que contêm azoto e sua utilização no aumento da eritropoetina endógena |
RU2373204C2 (ru) | 2003-07-28 | 2009-11-20 | Янссен Фармацевтика Н.В. | Бензимидазольные, бензтиазольные и бензоксазольные производные и их применение в качестве модуляторов lta4h |
JP4707560B2 (ja) | 2003-12-29 | 2011-06-22 | Msd株式会社 | 新規2−ヘテロアリール置換ベンズイミダゾール誘導体 |
JP2006022769A (ja) * | 2004-07-09 | 2006-01-26 | Toyota Motor Corp | 内燃機関の排気浄化装置 |
WO2006094292A2 (en) * | 2005-03-02 | 2006-09-08 | Fibrogen, Inc. | Thienopyridine compounds, and methods of use thereof |
JP2006254624A (ja) * | 2005-03-11 | 2006-09-21 | Fuji Electric Holdings Co Ltd | 交流交流変換器の制御装置 |
DE102005019712A1 (de) * | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
EP1893186A2 (en) * | 2005-06-06 | 2008-03-05 | Fibrogen, Inc. | Improved treatment for anemia using a hif-alpha stabilising agent |
WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
ES2274712B1 (es) * | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
US7728130B2 (en) | 2005-12-09 | 2010-06-01 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity |
JP5161793B2 (ja) | 2006-01-27 | 2013-03-13 | フィブロジェン, インコーポレイテッド | 低酸素症誘導因子(hif)を安定化するシアノイソキノリン化合物 |
TW200808793A (en) | 2006-03-07 | 2008-02-16 | Smithkline Beecham Corp | Prolyl hydroxylase inhibitors |
WO2007136990A2 (en) * | 2006-05-16 | 2007-11-29 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
PE20080209A1 (es) | 2006-06-23 | 2008-05-15 | Smithkline Beecham Corp | Derivados de glicina como inhibidores de prolil hidroxilasa |
EP4095127A1 (en) * | 2006-06-26 | 2022-11-30 | Akebia Therapeutics Inc. | Prolyl hydroxylase inhibitors and methods of use |
WO2008033739A2 (en) | 2006-09-12 | 2008-03-20 | Neurogen Corporation | Benzimidazole carboxamide derivatives |
DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
EP2132178B1 (en) | 2006-12-20 | 2015-08-19 | Merck Sharp & Dohme Corp. | Jnk inhibitors |
CL2008000066A1 (es) | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
CL2008000065A1 (es) * | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
CA2683956C (en) | 2007-04-18 | 2012-12-18 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
EP2136810A4 (en) | 2007-04-18 | 2012-01-04 | Merck Sharp & Dohme | NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS |
WO2008137084A2 (en) | 2007-05-04 | 2008-11-13 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
ES2389063T3 (es) | 2007-05-04 | 2012-10-22 | Amgen, Inc | Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa |
DE102007048447A1 (de) | 2007-10-10 | 2009-04-16 | Bayer Healthcare Ag | Substituierte Dihydropyrazolthione und ihre Verwendung |
DE102007049157A1 (de) | 2007-10-13 | 2009-04-16 | Bayer Healthcare Ag | Substituierte Dihydrotriazolone und ihre Verwendung |
EP2227475B1 (en) | 2007-12-03 | 2014-02-19 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
WO2009086044A1 (en) | 2007-12-19 | 2009-07-09 | Smith Kline Beecham Corporation | Prolyl hydroxylase inhibitors |
WO2009086592A1 (en) | 2008-01-04 | 2009-07-16 | Garvan Institute Of Medical Research | Method of increasing metabolism |
EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
AU2009217540B2 (en) | 2008-02-25 | 2013-10-10 | Merck Sharp & Dohme Corp. | Tetrahydrofuropyridones |
AU2009217541A1 (en) | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Tetrahydrothieno pyridines |
US8372863B2 (en) | 2008-02-25 | 2013-02-12 | Merck Sharp & Dohme Corp. | Tetrahydro-1H-pyrrolo fused pyridones |
CN102036981B (zh) | 2008-03-18 | 2015-04-08 | 默沙东公司 | 取代的4-羟基嘧啶-5-甲酰胺 |
US8759345B2 (en) | 2008-04-28 | 2014-06-24 | Janssen Pharmaceutica Nv | Benzoimidazoles as prolyl hydroxylase inhibitors |
EP2776023B1 (en) * | 2011-10-25 | 2016-03-09 | Janssen Pharmaceutica, N.V. | Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid |
-
2009
- 2009-04-28 US US12/990,104 patent/US8759345B2/en active Active
- 2009-04-28 JP JP2011507570A patent/JP6022769B2/ja not_active Expired - Fee Related
- 2009-04-28 DK DK09739552.9T patent/DK2294066T3/da active
- 2009-04-28 CA CA2722772A patent/CA2722772C/en active Active
- 2009-04-28 BR BRPI0911444A patent/BRPI0911444B8/pt not_active IP Right Cessation
- 2009-04-28 PT PT97395529T patent/PT2294066E/pt unknown
- 2009-04-28 CN CN200980126060.5A patent/CN102076680B/zh active Active
- 2009-04-28 EP EP09739552.9A patent/EP2294066B9/en active Active
- 2009-04-28 SI SI200931057T patent/SI2294066T1/sl unknown
- 2009-04-28 WO PCT/US2009/041902 patent/WO2009134750A1/en active Application Filing
- 2009-04-28 RU RU2010148421/04A patent/RU2531354C2/ru active
- 2009-04-28 WO PCT/US2009/041908 patent/WO2009134754A1/en active Application Filing
- 2009-04-28 ES ES09739552.9T patent/ES2523720T3/es active Active
- 2009-04-28 CN CN201610073238.6A patent/CN105622580B/zh active Active
- 2009-04-28 PL PL09739552T patent/PL2294066T3/pl unknown
-
2011
- 2011-09-14 HK HK11109678.7A patent/HK1155447A1/xx not_active IP Right Cessation
-
2013
- 2013-09-03 US US14/016,872 patent/US8865713B2/en active Active
-
2014
- 2014-05-20 US US14/282,901 patent/US9073923B2/en active Active - Reinstated
- 2014-09-30 CY CY20141100793T patent/CY1115621T1/el unknown
- 2014-10-28 HR HRP20141038TT patent/HRP20141038T2/hr unknown
-
2015
- 2015-06-05 US US14/732,332 patent/US20150284335A1/en not_active Abandoned
- 2015-12-14 US US14/968,763 patent/US20160168127A1/en not_active Abandoned
-
2016
- 2016-03-07 JP JP2016043107A patent/JP6254624B2/ja not_active Expired - Fee Related
-
2017
- 2017-09-05 US US15/695,958 patent/US20180215732A9/en not_active Abandoned
- 2017-11-30 JP JP2017229865A patent/JP2018065841A/ja not_active Withdrawn
-
2019
- 2019-03-07 US US16/295,476 patent/US10851083B2/en active Active
- 2019-06-18 JP JP2019112687A patent/JP6900424B2/ja active Active
-
2020
- 2020-11-24 US US17/103,482 patent/US11618744B2/en active Active
-
2021
- 2021-06-16 JP JP2021100045A patent/JP2021152045A/ja not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019167383A (ja) * | 2008-04-28 | 2019-10-03 | ヤンセン ファーマシューティカ エヌ.ベー. | プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6254624B2 (ja) | プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール | |
JP5643233B2 (ja) | プロリルヒドロキシラーゼ阻害物質としてのキナゾリノン | |
AU2015249140C1 (en) | Quinazolinones as prolyl hydroxylase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161212 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20170111 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20170315 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170411 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170711 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171031 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171130 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6254624 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees | ||
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |